Our Publications

Our team’s commitment to expanding the literature in patient-centered measurement has inspired hundreds of publications in numerous disease areas. Last update: August 2024

  1. Regnault A, Markowitz JT, Mazerolle F, Patel AM, Ciesluk A, Cano S, et al. A single metric for Pediatric and Adult versions of patient reported outcome measures: illustration in haemophilia. ISOQOL; 2019; San Diego, CA, USA.
  2. Regnault A, Raimundo K, Patel AM, et al. Is the Comprehensive Assessment Tool of Challenges in Hemophilia (CATCH) appropriate to measure the impact of hemophilia and its treatment? First quantitative survey. American Thrombosis and Hemostasis Network data summit; 2019; Chicago, IL, USA.
  3. Regnault A, Raimundo K, Patel AM, Markowitz JT, Marquis P, Shapiro AD, et al. Is the Comprehensive Assessment Tool of Challenges in Hemophilia (CATCH) appropriate to measure the impact of hemophilia and its treatment? First quantitative survey Hemostasis & Thrombosis Research Society; New Orleans, LA, USA, 2019.
  4. Markowitz JT, Patel AM, Raimundo K, Marquis P, Shapiro AD, Konkle BA, et al. Early patient experiences with emicizumab in the United States: a qualitative study. International Society on Thrombosis and Haemostasis Congress; Melbourne, Australia, 2019.
  5. Markowitz JT, Ma E, Solari PG, Marquis P, Shapiro AD, Konkle BA, et al. Development of a Concept-Driven Disease Impact Instrumentfrom Patients with Hemophilia (Pediatric and Adult) and Caregivers. American Thrombosis and Hemostasis Network Data Summit; Chicago, IL, USA, 2018.
  6. Markowitz JT, Ma E, Solari PG, Marquis P, Shapiro AD, Konkle BA, et al. Development of a Concept-Driven Disease Impact Instrument from Patients with Hemophilia (Pediatric and Adult) and Caregivers. American Society of Hematology; Atlanta, GA, USA, 2017.
  7. Carcao M, Kearney S, Santagostino E, Oyesiku JO, Young NL, Meunier J, et al. Insight into health-related quality of life of young children with haemophilia B treated with long-acting nonacog beta pegol recombinant factor IX. Haemophilia. 2017;23(3):e222-4.
  8. Chowdary P, Kearney S, Regnault A, Hoxer CS, Yee DL. Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product. Haemophilia. 2016;22(4):e267-74.
  9. Seremetis S, Kulkarni R, Regnault A, Santagostino E. Turoctocog alfa in the treatment of individuals with hemophilia A: review of quality of life data collected in Phase III trials. Clinical Investigation. 2015;5(9):755-66.
  10. Ozelo M, Meunier J, Hoxer CS, Slothuus U. Quality of life and satisfaction of adults with haemophilia A switched to prophylactic treatment with recombinant factor VIII turoctocog alfa. EAHAD; Helsinki, Finland, 2015.
  11. Ozelo M, Chowdary P, Regnault A, Busk AK. Impact of severe haemophilia A on patients' health status: results from the guardian™ 1 clinical trial of turoctocog alfa (NovoEight®). Haemophilia. 2015;21(4):451-7.
  12. Chowdary P, Kearney S, Yee D, Meunier J, Slothuus U, Hoxer CS. Improved health status of haemophilia B patients treated with nonacog beta pegol, a new glycopegylated recombinant FIX product with prolonged half-life. ISPOR; Philadelphia, USA, 2015.
  13. Chowdary P, Kearney S, Yee D, Meunier J, Slothuus U, Hoxer C. Improved health-related quality of life (HRQoL) of haemophilia B patients treated with a weekly 40IU/kg dose of a new long-acting recombinant factor IX (FIX) product, nonacog beta pegol. International Society of Thrombosis and Haemostasis (ISTH); 2015; Toronto, ON, Canada, 2015.
  14. Santagostino E, Lentz SR, Busk AK, Regnault A, Iorio A. Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa. Haemophilia. 2014;20(4):527-34.
  15. Ozelo M, Chowdary P, Regnault A, Busk AK. Impact of severe haemophilia A on patients’ health status: results from the guardian™ 1 clinical trial of turoctocog alfa. World Federation of Hemophilia Congress; Melbourne, Australia, 2014.
  16. Santagostino E, Lentz S, Iorio A, Busk A, Abad Franch L, Meunier J, et al. Effect of turoctocog alfa on quality of life of children, adolescents and adults with haemophilia A: Results from two clinical trials. 6th Annual Congress of the European Association for Haemophilia and Allied Disorders; Warsaw, Poland, 2013.
  1. Klassen AF, Grant C, Barr R, Brill H, Kraus de Camargo O, Ronen GM, et al. Development and validation of a generic scale for use in transition programs to measure self-management skills in adolescents with chronic health conditions: the TRANSITION-Q. Child: care, health and development. 2015;41(4):547-58.
  2. Arnould B, Gauchoux R, Meunier J, Gilet H, Regnault A. Validation of ACCEPT, a new generic measure to assess how patients with chronic diseases balance between the advantages and disadvantages of following the recommended treatment regimen in real-life. ISPOR; Dublin, Ireland, 2013.
  1. Watanabe-Fujinuma E, Banderas BF, Koretsune Y, Kumagai K, Uchiyama S, Yamashita T, Yasaka M, Akiyama S, Briere JB, Dickie G, Cano SJ. Psychometric validation of anti-clot treatment scale and treatment satisfaction questionnaire for medication version II in Japanese patients with atrial fibrillation. Journal of medical economics. 2019;22(8):798-805.
  2. Koretsune Y, Kumagai K, Uchiyama S, Yamashita T, Yasaka M, Watanabe-Fujinuma E, et al. Patient-reported treatment satisfaction with rivaroxaban in Japanese non-valvular atrial fibrillation patients: an observational study. Current medical research and opinion. 2018:1-8.
  3. Cano S, Mantovani L, Folkerts K, Gebel M, Sahin K, Zell E, et al. Patient-Reported Treatment Experience with Oral Rivaroxaban: Results from the Noninterventional XALIA Study of Deep-Vein Thrombosis. TH Open. 2018;02(02):e139-e46.
  4. Diab M, Bilkhu R, Soppa G, McGale N, Hirani SP, Newman SP, et al. Quality of Life in Relation to Length of Intensive Care Unit Stay After Cardiac Surgery. Journal of cardiothoracic and vascular anesthesia. 2017;31(3):1080-90.
  5. Beaney KE, Ward CE, Bappa DA, McGale N, Davies AK, Hirani SP, et al. A 19-SNP coronary heart disease gene score profile in subjects with type 2 diabetes: the coronary heart disease risk in type 2 diabetes (CoRDia study) study baseline characteristics. Cardiovascular diabetology. 2016;15(1):141.
  6. Prins MH, Bamber L, Cano SJ, Wang MY, Erkens P, Bauersachs R, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis research. 2015;135(2):281-8.
  7. Diab M, Soppa G, McGale N, Hirani SP, Newman S, Jahangiri M. Quality of Life and functional status following cardiac surgery. Society for Cardiothoracic Surgery in Great Britain and Ireland; Manchester, UK, 2015.
  8. Davies AK, McGale N, Humphries SE, Hirani SP, Beaney KE, Bappa DA, et al. Effectiveness of a self-management intervention with personalised genetic and lifestyle-related risk information on coronary heart disease and diabetes-related risk in type 2 diabetes (CoRDia): study protocol for a randomised controlled trial. Trials. 2015;16:547.
  9. Sosner P, Fiquet B, Quere S, Francillon A, Herpin D. How are physicians prescribing the direct renin inhibitor aliskiren in the management of essential hypertension? A French observational study. Journal of hypertension. 2013;31(7):1491-6; discussion 6.
  10. Bonner N, Abetz L, Meunier J, Sikirica M, Mathai SC. Development and validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients. Health QualLife Outcomes. 2013;11(1):161.
  11. Bamber L, Wang MY, Prins MH, Ciniglio C, Bauersachs R, Lensing AW, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and haemostasis. 2013;110(4):732-41.
  12. Mounier-Vehier C, Simon T, Guedj-Meynier D, Ferrini M, Ghannad E, Hubermann JP, et al. Gender-related differences in the management of hypertension by cardiologists: the PARITE study. Archives of cardiovascular diseases. 2012;105(5):271-80.
  13. Cano SJ, Lamping DL, Bamber L, Smith S. The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patients. Health Qual Life Outcomes. 2012;10:120.
  14. Cano S, Bamber L, Lamping D. Comparing oral rivaroxaban versus standard treatment in the treatment of symptomatic deep vein thrombosis: a patient-reported treatment satisfaction study. 17th Congress of the European association of hospital pharmacists; Milan, Italy, 2012.
  15. Asmar R, Gosse P, Quere S, Achouba A. Efficacy of morning and evening dosing of amlodipine/valsartan combination in hypertensive patients uncontrolled by 5 mg of amlodipine. Blood pressure monitoring. 2011;16(2):80-6.
  16. Marquis P, Le Gal M, Francillon A, Andre-Fouet X. [Quality of life and angina pectoris. Comparison of the effects of 2 nitrate derivatives administered discontinuously: transdermal 10 mg nitroglycerine patch (12 hours) and long-acting oral 40 mg isosorbide-5-mononitrate (once a day)]. Ann Cardiol Angeiol (Paris). 2001;50(6):340-50.
  17. Marquis P, Comte S, Lehert P. International validation of the CLAU-S quality-of-life questionnaire for use in patients with intermittent claudication. Pharmacoeconomics. 2001;19(6):667-77.
  18. Selke B, Marquis P, Lebrun T. [Socioeconomic and quality of life repercussions of arterial hypertension]. Drugs. 1998;56 Suppl 2:45-53.
  19. Marquis P, Fayol C, Joire JE, Leplege A. Psychometric properties of a specific quality of life questionnaire in angina pectoris patients. Qual Life Res. 1995;4(6):540-6.
  20. Marquis P, Fayol C, Joire JE. Clinical validation of a quality of life questionnaire in angina pectoris patients. Eur Heart J. 1995;16(11):1554-60.
  21. Marquis P, Fayol C, McCarthy C, Fiessinger JN. [Measurement of quality of life in intermittent claudication. Clinical validation of a questionnaire]. Presse Med. 1994;23(28):1288-92.
  1. Klassen AF, Cano SJ, Schwitzer JA, Baker SB, Carruthers A, Carruthers J, et al. Development and Psychometric Validation of the FACE-Q Skin, Lips, and Facial Rhytids Appearance Scales and Adverse Effects Checklists for Cosmetic Procedures. JAMA Dermatol. 2016;152(4):443-51.
  2. Klassen AF, Cano SJ, Pusic AL. Use of FACE-Q to Measure Quality of Life Following Aesthetic Facial Treatments. JAMA Facial Plast Surg. 2016;18(2):148-9.
  3. Klassen AF, Cano SJ, Pusic AL. FACE-Q Satisfaction with Appearance Scores from Close to 1000 Facial Aesthetic Patients. Plast Reconstr Surg. 2016;137(3):651e-2e.
  4. Klassen AF, Cano SJ, Alderman A, East C, Badia L, Baker SB, et al. Self-Report Scales to Measure Expectations and Appearance-Related Psychosocial Distress in Patients Seeking Cosmetic Treatments. Aesthet Surg J. 2016;36(9):1068-78.
  5. Schwitzer J, Klassen AF, Cano SJ, Pusic AL. Towards Evidence-Based Practice in Cosmetic Surgery Using the Q-Portfolio of Patient-Reported Outcome Measures Aesthetic Journal. 2014;1(7):28-32.
  6. Wildgoose P, Scott A, Pusic AL, Cano S, Klassen AF. Psychological screening measures for cosmetic plastic surgery patients: a systematic review. Aesthet Surg J. 2013;33(1):152-9.
  7. Pusic AL, Klassen AF, Scott AM, Cano SJ. Development and psychometric evaluation of the FACE-Q satisfaction with appearance scale: a new patient-reported outcome instrument for facial aesthetics patients. Clinics in plastic surgery. 2013;40(2):249-60.
  8. McCarthy CM, Cano SJ, Klassen AF, Scott A, Van Laeken N, Lennox PA, et al. The magnitude of effect of cosmetic breast augmentation on patient satisfaction and health-related quality of life. Plast Reconstr Surg. 2012;130(1):218-23.
  9. Pusic AL, Reavey PL, Klassen AF, Scott A, McCarthy C, Cano SJ. Measuring patient outcomes in breast augmentation: introducing the BREAST-Q Augmentation module. Clinics in plastic surgery. 2009;36(1):23-32, v.
  1. Harris SA, Lamping DL, Brown EA, Constantinovici N, Phillips M, Barnes G, et al. Clinical outcomes and quality of life in elderly patients on peritoneal dialysis versus hemodialysis. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis. 2002;22(4):463-70.
  1. Lamarca A, Elliott E, Barriuso J, et al. Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause? Cancer Treat Rev. 2016;44:26-41.
  2. Marquis P, Lasch KE, Delgado-Herrera L, Kothari S, Lembo A, Lademacher C, et al. Qualitative development of a patient-reported outcome symptom measure in diarrhea-predominant irritable bowel syndrome. Clin Transl Gastroenterol. 2014;5:e59.
  3. Markowitz JT. Coping with Challenges of a Dual Diagnosis (of Diabetes and Celiac Disease) – Counseling Strategies. Annual Meeting of the American Diabetes Association; 2013; Chicago, USA.
  4. Regnault A, Siliman G, Dubois D, Kerstens R, Marant C. Development of symptom indices using formative structural equation models: Application to the PAC-SYM questionnaire. International Society for Clinical Biostatistics; Montpellier, France, 2010.
  5. Regnault A, Siliman G, Dubois D, Kerstens R, Marant C. Development of symptom measures reflecting the relative impact of symptoms on Health-Related Quality of Life: Application to chronic constipation. ISOQOL; 2010; London, UK.
  6. Mear I, Conway K, Regnault A, Acquadro C. Similarities and Differences in the Expression of Symptoms Across Countries: The Translations of the PAGI-SYM 20. ISOQOL; 2010; London, UK.
  7. Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol. 2005;40(5):540-51.
  8. De La Loge C, Trudeau E, Marquis P, Revicki DA, Rentz AM, Stanghellini V, et al. Responsiveness and interpretation of a quality of life questionnaire specific to upper gastrointestinal disorders. Clin Gastroenterol Hepatol. 2004;2(9):778-86.
  9. Arnould B, Regnault A, Dubois D. Diagnosis of Upper Gastro-Intestinal Disorders: Comparing three Methods to Shorten a Predictive Symptom Checklist. European Society for Medical Decision Making 9th Biennial Conference; Rotterdam, The Netherlands, 2004.
  10. Arnould B, Regnault A, Dubois D. Using partial least squares (PLS) analysis to shorten a predictive symptom checklist for upper gastro-intestinal (UGI) disorders. ISOQOL symposium; Boston, USA, 2004.
  11. Marquis P, Marrel A, Jambon B. Quality of life in patients with stomas: the Montreux Study. Ostomy Wound Manage. 2003;49(2):48-55.
  12. Pigot F, Castinel A, Juguet F, Marrel A, Deroche C, Marquis P. [Quality of life, symptoms of dyschezia, and anatomy after correction of rectal motility disorder]. Gastroenterol Clin Biol. 2001;25(2):154-60.
  13. Levenstein S, Li Z, Almer S, Barbosa A, Marquis P, Moser G, et al. Cross-cultural variation in disease-related concerns among patients with inflammatory bowel disease. Am J Gastroenterol. 2001;96(6):1822-30.
  14. Blondel-Kucharski F, Chircop C, Marquis P, Cortot A, Baron F, Gendre JP, et al. Health-related quality of life in Crohn's disease: a prospective longitudinal study in 231 patients. Am J Gastroenterol. 2001;96(10):2915-20.
  15. Sacher-Huvelin S, Gournay J, Amouretti M, Marquis P, Bruley Des Varannes S, Galmiche JP. [Acid-sensitive esophagus: natural history and effect on the quality of life. Comparison with gastroesophageal reflux]. Gastroenterol Clin Biol. 2000;24(10):911-6.
  16. Raymond JM, Marquis P, Bechade D, Smith D, Mathiex Fortunet H, Poynard T, et al. [Assessment of quality of life of patients with gastroesophageal reflux. Elaboration and validation of a specific questionnaire]. Gastroenterol Clin Biol. 1999;23(1):32-9.
  17. Louis E, Marquis P, Nalet B. [How does one evaluate the severity of gastroesophageal reflux and what are the therapeutic objectives?]. Revue medicale de Bruxelles. 1999;20(2):A114-5.
  18. Enck P, Dubois D, Marquis P. Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl. 1999;231:48-54.
  19. Chassany O, Marquis P, Scherrer B, Read NW, Finger T, Bergmann JF, et al. Validation of a specific quality of life questionnaire for functional digestive disorders. Gut. 1999;44(4):527-33.
  20. Yazdanpanah Y, Klein O, Gambiez L, Baron P, Desreumaux P, Marquis P, et al. Impact of surgery on quality of life in Crohn's disease. Am J Gastroenterol. 1997;92(10):1897-900.
  21. Colombel JF, Yazdanpanah Y, Laurent F, Houcke P, Delas N, Marquis P. [Quality of life in chronic inflammatory bowel diseases. Validation of a questionnaire and first French data]. Gastroenterol Clin Biol. 1996;20(12):1071-7.
  22. Rampal P, Martin C, Marquis P, Ware JE, Bonfils S. A quality of life study in five hundred and eighty-one duodenal ulcer patients. Maintenance versus intermittent treatment with nizatidine. Scand J Gastroenterol Suppl. 1994;206:44-51.
  23. Martin C, Marquis P, Bonfils S. A 'quality of life questionnaire' adapted to duodenal ulcer therapeutic trials. Scand J Gastroenterol Suppl. 1994;206:40-3.
  1. Shapira A, Volkening LK, Markowitz JT, Butler DA, Laffel LM. Mental Health Providers' Assessment of Parents' Reactions to their Children's Elevated Depressive Symptoms. Pediatric Diabetes. 2020:1-6.
  2. Simon A, Pompilus F, Querbes W, Wei A, Strzok S, Penz C, et al. Patient Perspective on Acute Intermittent Porphyria with Frequent Attacks: A Disease with Intermittent and Chronic Manifestations. The Patient - Patient-Centered Outcomes Research. 2018.
  3. Senior E, Fong R, Christian A, Markowitz JT, Strzok S, Schmidt T, et al. Impacts of Type 1 Diabetes on Patients during the First Two Years—A Qualitative Research Study. Diabetes. 2018;67(Supplement 1):2338-PUB.
  4. Klassen AF, Kaur M, Breitkopf T, Thoma A, Cano S, Pusic A. Using the BODY-Q to Understand Impact of Weight Loss, Excess Skin and the Need for Body Contouring Following Bariatric Surgery. Plast Reconstr Surg. 2018.
  5. Simon A, Pompilus F, Querbes W, Penz C, Agarwal S, Strzok S, et al. A qualitative analysis of disease burden in patients with acute intermittent porphyria and recurrent attacks. ISPOR; Boston, MA, USA, 2017.
  6. Regnault A, Denoncourt RN, Strahs A, Agarwal S, Marquis P, Cano S. Measurement properties of the Rasch-built overall disability scale in patients with hereditary ATTR Amyloidosis with polyneuropathy. ISPOR; Boston, MA, USA, 2017.
  7. Klassen AF, Cano SJ, Kaur M, Breitkopf T, Pusic AL. Further psychometric validation of the BODY-Q: ability to detect change following bariatric surgery weight gain and loss. Health Qual Life Outcomes. 2017;15(1):227.
  8. Young-Hyman DL, Peterson CM, Fischer S, Markowitz JT, Muir AB, Laffel LM. Depressive Symptoms, Emotion Dysregulation, and Bulimic Symptoms in Youth With Type 1 Diabetes: Varying Interactions at Diagnosis and During Transition to Insulin Pump Therapy. J Diabetes Sci Technol. 2016;10(4):845-51.
  9. Hevelke LK, Albrecht C, Busse-Widmann P, Kranz J, Lange K, Markowitz JT, et al. [Prevalence of Disturbed Eating Behavior in Children and Adolescents with Type 1 Diabetes: Assessment and Comparison to Healthy Peers--Results of a Multicenter Questionnaire-based Study]. Psychother Psychosom Med Psychol. 2016;66(3-4):128-35.
  10. Halimi JM, Joly D, Combe C, Choukroun G, Dussol B, Fauvel JP, et al. Blood pressure and proteinuria control remains a challenge in patients with type 2 diabetes mellitus and chronic kidney disease: experience from the prospective observational ALICE-PROTECT study. BMC nephrology. 2016;17(1):135.
  11. Grimaldi A, Penfornis A, Consoli S, Falissard B, Eymard E, Meunier J, et al. Supprimer les barrières à une gestion du diabète de type 2 efficace: résultats de l'utilisation de l'outil OPTIMA en pratique courante. Société Francophone du Diabète; Lyon, France, 2016.
  12. Beaney KE, Ward CE, Bappa DA, McGale N, Davies AK, Hirani SP, et al. A 19-SNP coronary heart disease gene score profile in subjects with type 2 diabetes: the coronary heart disease risk in type 2 diabetes (CoRDia study) study baseline characteristics. Cardiovascular diabetology. 2016;15(1):141.
  13. Sassmann H, Albrecht C, Busse-Widmann P, Hevelke LK, Kranz J, Markowitz JT, et al. Psychometric properties of the German version of the Diabetes Eating Problem Survey-Revised: additional benefit of disease-specific screening in adolescents with Type 1 diabetes. Diabet Med. 2015;32(12):1641-7.
  14. Regnault A, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Benmedjahed K, et al. Development and psychometric validation of measures to assess the impact of phenylketonuria and its dietary treatment on patients' and parents' quality of life: the phenylketonuria - quality of life (PKU-QOL) questionnaires. Orphanet J Rare Dis. 2015;10:59.
  15. Rasbach LE, Volkening LK, Markowitz JT, Butler DA, Katz ML, Laffel LM. Youth and parent measures of self-efficacy for continuous glucose monitoring: survey psychometric properties. Diabetes Technol Ther. 2015;17(5):327-34.
  16. Markowitz JT, Volkening LK, Butler DA, Laffel LM. Youth-Perceived Burden of Type 1 Diabetes: Problem Areas in Diabetes Survey-Pediatric Version (PAID-Peds). J Diabetes Sci Technol. 2015;9(5):1080-5.
  17. Markowitz JT, Garvey KC, Laffel LM. Developmental changes in the roles of patients and families in type 1 diabetes management. Curr Diabetes Rev. 2015;11(4):231-8.
  18. Klassen A, Alderman A, Soldin M, Robson S, Kaur M, Cano S, et al. Development and psychometric validation of a PRO instrument for obese, bariatric and cosmetic body contouring patients: the BODY-Q. ISOQOL; 2015; Vancouver, Canada
  19. Joly D, Choukroun G, Combe C, Dussol B, Fauvel JP, Halimi JM, et al. Glycemic control according to glomerular filtration rate in patients with type 2 diabetes and overt nephropathy: a prospective observational study. Diabetes research and clinical practice. 2015;108(1):120-7.
  20. Duclos M, Dejager S, Postel-Vinay N, di Nicola S, Quere S, Fiquet B. Physical activity in patients with type 2 diabetes and hypertension--insights into motivations and barriers from the MOBILE study. Vascular health and risk management. 2015;11:361-71.
  21. Davies AK, McGale N, Humphries SE, Hirani SP, Beaney KE, Bappa DA, et al. Effectiveness of a self-management intervention with personalised genetic and lifestyle-related risk information on coronary heart disease and diabetes-related risk in type 2 diabetes (CoRDia): study protocol for a randomised controlled trial. Trials. 2015;16:547.
  22. Bosch AM, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Koledova E, et al. Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries. Orphanet J Rare Dis. 2015;10:80.
  23. Rasbach LE, Volkening LK, Gaffney KC, Markowitz JT, Laffel LM. Evaluation of a New Youth and Parent Measure to Assess Self-Efficacy for Continuous Glucose Monitoring (CGM) in Youth with Type 1 Diabetes (T1D). Annual Meeting of the American Diabetes Association; San Francisco, USA, 2014.
  24. Penfornis A, Blickle JF, Fiquet B, Quere S, Dejager S. How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study. Vascular health and risk management. 2014;10:341-52.
  25. Markowitz JT, Volkening LK, Laffel LM. Care utilization in a pediatric diabetes clinic: cancellations, parental attendance, and mental health appointments. J Pediatr. 2014;164(6):1384-9.
  26. Markowitz JT, Cousineau T, Franko DL, Schultz AT, Trant M, Rodgers R, et al. Text messaging intervention for teens and young adults with diabetes. J Diabetes Sci Technol. 2014;8(5):1029-34.
  27. Markowitz JT, Christian AJ, Cartaya JB, Laffel LM. Teen and Parent Perceptions of the Transition Process from Pediatric to Adult Care in Type 1 Diabetes (T1D): A Qualitative Study. Annual Meeting of the American Diabetes Association; San Francisco, USA, 2014.
  28. Markowitz JT. Depression Screening in Pediatric Type 1 Diabetes (T1D); Positive Screening Scores and Parental Responses. Annual Meeting of the Society for Behavioral Medicine; 2014; Philadelphia, USA.
  29. Harrington KR, Barstow MB, Volkening LK, Markowitz JT, Butler DA, Laffel LM. Reexamining Fear of Hypoglycemia (FOH) Survey in Contemporary Youth with Type 1 Diabetes (T1D) and their Parents. Annual Meeting of the American Diabetes Association; San Francisco, USA, 2014.
  30. Goebel-Fabbri A, Markowitz JT, Zrebiec J, Butler A, DiVincenzo R, Ritholz MD. Who are the Patients Utilizing Behavioral Mental Health (MH) Services at a Comprehensive Diabetes Center? Annual Meeting of the American Diabetes Association; San Francisco, USA, 2014.
  31. Bosch AM, Burlina A, Cunningham A, Bettiol EO, Moreau-Stucker F, Benmedjahed K, et al. Psychometric Validation of the Newly Developed Phenylketonuria- Quality of Life (Pku-Qol) Questionnaires Assessing the Impact of Phenylketonuria and Its Treatment On Patients' Quality of Life. ISPOR; Amsterdam, The Netherlands, 2014.
  32. Bosch A, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Benmedjahed K, et al. Psychometric validation of questionnaires assessing the impact of phenylketonuria on patients and caregivers’ quality of life. ISPOR; Amsterdam, The Netherlands, 2014.
  33. Bosch A, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Benmedjahed K, et al. Development and validation of disease-specific quality of life questionnaires for individuals with phenylketonuria and their parents. Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium; Innsbruck, Austria, 2014.
  34. Markowitz JT, Volkening LK, Laffel LMB. Development of a Parent Proxy Diabetes-Specific Transition Readiness Questionnaire. Annual Meeting of the American Diabetes Association; Chicago, USA, 2013.
  35. Markowitz JT, Harrington KR, Laffel LM. Technology to optimize pediatric diabetes management and outcomes. Curr Diab Rep. 2013;13(6):877-85.
  36. Markowitz JT, Butler DA, Volkening LK, Laffel LM. Youth-Perceived Burden of Type 1 Diabetes (T1D): Problem Areas in Diabetes – Pediatric Survey (PAID-PEDS). Annual Meeting of the American Diabetes Association; Chicago, USA, 2013.
  37. Markowitz JT, Alleyn CA, Phillips R, Muir A, Young-Hyman D, Laffel LM. Disordered eating behaviors in youth with type 1 diabetes: prospective pilot assessment following initiation of insulin pump therapy. Diabetes Technol Ther. 2013;15(5):428-33.
  38. Markowitz JT. Coping with Challenges of a Dual Diagnosis (of Diabetes and Celiac Disease) – Counseling Strategies. Annual Meeting of the American Diabetes Association; 2013; Chicago, USA.
  39. Markowitz JT. Beyond Medical Management: Psychosocial Challenges in Youth with Diabetes. School Nurse Training Program, Joslin Diabetes Center; 2013; Boston, USA.
  40. Harrington KR, Markowitz JT, Volkening LK, Katz ML, Laffel LMB. Impact of Mental Health (MH) on Fear of Hypoglycemia (FOH), Glycemic Control, and Quality of Life (QOL) in Youth with Type 1 Diabetes (T1D). Annual Meeting of the American Diabetes Association; Chicago, USA, 2013.
  41. Halimi S, Levy M, Huet D, Quere S, Dejager S. Experience with Vildagliptin in Type 2 Diabetic Patients Fasting During Ramadan in France: Insights from the VERDI Study. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2013;4(2):385-98.
  42. Penfornis A, Bourdel-Marchasson I, Quere S, Dejager S. Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: the HYPOCRAS study. Diabetes & metabolism. 2012;38(6):550-7.
  43. Markowitz JT, Volkening LK, Butler DA, Antisdel-Lomaglio J, Anderson BJ, Laffel LM. Re-examining a measure of diabetes-related burden in parents of young people with Type 1 diabetes: the Problem Areas in Diabetes Survey - Parent Revised version (PAID-PR). Diabet Med. 2012;29(4):526-30.
  44. Markowitz JT, Pratt K, Aggarwal J, Volkening LK, Laffel LM. Psychosocial correlates of continuous glucose monitoring use in youth and adults with type 1 diabetes and parents of youth. Diabetes Technol Ther. 2012;14(6):523-6.
  45. Markowitz JT, Mickey SS, Fisher EA, Haynie D, Nansel TR, Mehta SN, et al. Implications of Family History (FHx) of Diabetes (DM) for Youth with Type 1 Diabetes (T1D). Annual Meeting of the American Diabetes Association; Philadelphia, USA, 2012.
  46. Markowitz JT, Laffel LM. Transitions in care: support group for young adults with Type 1 diabetes. Diabet Med. 2012;29(4):522-5.
  47. Markowitz JT, Laffel LM. Frequency of Missed Clinic Visits and Family Member Visit Attendance by Provider in a Pediatric, Adolescent, and Young Adult Diabetes Clinic. Annual Meeting of the American Diabetes Association; Philadelphia, USA, 2012.
  48. Markowitz JT, Butler DA, Laffel LM. Utilization of mental health care in a pediatric diabetes clinic. Annual Meeting of the American Diabetes Association; Philadelphia, USA, 2012.
  49. Markowitz JT. Psychosocial Challenges of Diabetes in Young Adults. Department of Social Work Grand Rounds, Beth Israel Deaconess Medical Center; 2012; Boston, USA.
  50. Markowitz JT. Building Family Support: Case Examples of Type 1 Diabetes Treatment Issues. CME program, Joslin Diabetes Center; 2012; Boston, USA.
  51. Markowitz JT. Clinical Issues in the Behavioral Management of Diabetes. Training for psychology interns/post-doctoral fellows, Massachusetts General Hospital; 2012; Boston, USA.
  52. Markowitz JT. Troubleshooting Challenging Situations. School Nurse Training Program, Joslin Diabetes Center; 2012; Boston, USA.
  53. Guerci B, Monnier L, Serusclat P, Petit C, Valensi P, Huet D, et al. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Diabetes & metabolism. 2012;38(4):359-66.
  54. Garvey KC, Markowitz JT, Laffel LM. Transition to adult care for youth with type 1 diabetes. Curr Diab Rep. 2012;12(5):533-41.
  55. Gagnon C, Aime A, Belanger C, Markowitz JT. Comorbid diabetes and eating disorders in adult patients: assessment and considerations for treatment. Diabetes Educ. 2012;38(4):537-42.
  56. Young-Hyman D, Laffel LM, Markowitz JT, Norman J, Muir A, Lindsley K. Evaluating Eating Disorder Risk (EDR) in T1D Youth Transitioning to Insulin Pump (CSII) Therapy (Rx). Annual Meeting of the American Diabetes Association; San Diego, USA, 2011.
  57. Young-Hyman D, Laffel LM, Markowitz JT, Norman J, Muir A, Lindsley K. Evaluating Eating Disorder Risk at Time of Teen T1D Diagnosis (DX). Annual Meeting of the American Diabetes Association; San Diego, USA, 2011.
  58. Markowitz JT, Laffel LM, Volkening LK, Anderson BJ, Nansel TR, Weissberg-Benchell J, et al. Validation of an abbreviated adherence measure for young people with Type 1 diabetes. Diabet Med. 2011;28(9):1113-7.
  59. Markowitz JT, Alleyn CA, Phillips R, Muir A, Young-Hyman D, Laffel LMB. Disordered eating behaviors in youth with type 1 diabetes initiating pump therapy: baseline and after 6 weeks. Annual Meeting of the International Society for Pediatric and Adolescent Diabetes; Miami, USA2011.
  60. Markowitz JT. Special Considerations in Caring for Young Adults with Type 1 Diabetes. Clinic Staff Education Forum, Joslin Diabetes Center; 2011; Boston, USA.
  61. Young-Hyman D, Laffel LM, Muir A, Davis C, Alleyn C, Markowitz JT. Baseline psychological and weight characteristics: The Treatment and Weight Concerns (TaWC) cohort. Diabetes 2010;59((Suppl 1)):A701-2.
  62. Markowitz JT, Volkening LK, Laffel LMB, Anderson BJ, Nansel TR, Weissberg-Benchell J, et al. Validation of an Abbreviated Adherence Measure in Youth with Type 1 Diabetes (T1D). Annual Meeting of the American Diabetes Association; Orlando, USA, 2010.
  63. Markowitz JT, Butler DA, Volkening LK, Antisdel JE, Anderson BJ, Laffel LM. Brief screening tool for disordered eating in diabetes: internal consistency and external validity in a contemporary sample of pediatric patients with type 1 diabetes. Diabetes Care. 2010;33(3):495-500.
  64. Markowitz JT. Identifying Disordered Eating Behaviors in Pediatric Patients with Type 1 Diabetes. CME program, Joslin Diabetes Center; 2010; Boston, USA.
  65. Butler DA, Volkening LK, Lochrie AS, Markowitz JT, Murphy HG, Laffel LMB, et al. Diabetes-Specific Management Goals Selected by Families to Optimize Glycemic Control During Childhood Type 1 Diabetes (T1D). Annual Meeting of the American Diabetes Association; Orlando, USA, 2010.
  66. Markowitz JT, Volkening LK, Butler DA, Anderson BJ, Laffel LMB. A Brief Screening Measure of Disordered Eating in Diabetes. Annual Meeting of the American Diabetes Association; New Orleans, USA, 2009.
  67. Markowitz JT, Lowe MR, Volkening LK, Laffel LM. Self-reported history of overweight and its relationship to disordered eating in adolescent girls with Type 1 diabetes. Diabet Med. 2009;26(11):1165-71.
  68. Thomas G, Markowitz JT, Tappe K, Chernyak Y, Ochner C, Butryn M, et al. Telephone-based weight loss maintenance interventions for patients referred from primary care clinics. Annual Meeting of The Obesity Society; Phoenix, USA, 2008.
  69. Sarwer D, Thomas G, Markowitz JT, Eisenberg M, Sywulak L. Medical weight management prior to bariatric surgery: preliminary results. Annual Meeting of The Obesity Society; Phoenix, USA, 2008.
  70. Markowitz JT. Evidence-Based Treatment of Eating Disorders and Obesity. Staff training, United Counseling Services; 2007; Bennington, VT, USA.
  71. Arnould B, Benmedjahed K, Consoli S, Gueron B, Guillemin I, Meunier J, et al. Development, scoring and initial validation of a self-administered questionnaire for diabetic profiling based on patient attitude towards insulin. ISOQOL Budapest, Hungary, 2007.
  72. Sarwer DB, Allison KC, Gibbons LM, Markowitz JT, Nelson DB. Pregnancy and obesity: a review and agenda for future research. J Womens Health (Larchmt). 2006;15(6):720-33.
  73. Markowitz JT, Tappe K, Brody D, Lowe M. Predictors of participation in a study of weight loss maintenance in African American women. Annual Meeting of the North American Association for the Study of Obesity; Boston, MA, 2006.
  74. Markowitz JT. Treatment of Obesity and Eating Disorders. Drexel University Student Counseling Center Staff; 2006; Philadelphia, USA.
  1. Browne JP, Hopkins C, Slack R, Cano SJ. The Sino-Nasal Outcome Test (SNOT): can we make it more clinically meaningful? Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2007;136(5):736-41.
  2. Berdeaux G, Hervie C, Smajda C, Marquis P. Parental quality of life and recurrent ENT infections in their children: development of a questionnaire. Rhinitis Survey Group. Qual Life Res. 1998;7(6):501-12.
  1. Williams P, McBain H, Amirova A, Newman S, Mulligan K. Men's beliefs about treatment for erectile dysfunction-what influences treatment use? A systematic review. Int J Impot Res. 2020.
  2. Williams P, Bandhoo S, McBain H, Mulligan K, Steggall MJ. The prevalence of erectile dysfunction in men attending cardiac rehabilitation: an audit in East London. International Journal of Urological Nursing. 2017;11(1):23-30.
  3. Halimi JM, Joly D, Combe C, Choukroun G, Dussol B, Fauvel JP, Quere S, Fiquet B. Blood pressure and proteinuria control remains a challenge in patients with type 2 diabetes mellitus and chronic kidney disease: experience from the prospective observational ALICE-PROTECT study. BMC nephrology. 2016;17(1):135.
  4. Williams P, Bandhoo S, McBain H, Mulligan K, Steggall MJ. Erectile dysfunction and its detection in the healthcare setting: 10 years on. Int J Clin Pract. 2015;69(8):910-911.
  5. Rostaing L, Hertig A, Albano L, Anglicheau D, Durrbach A, Vuiblet V, et al. Fibrosis progression according to epithelial-mesenchymal transition profile: a randomized trial of everolimus versus CsA. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2015;15(5):1303-12.
  6. Joly D, Choukroun G, Combe C, Dussol B, Fauvel JP, Halimi JM, et al. Glycemic control according to glomerular filtration rate in patients with type 2 diabetes and overt nephropathy: a prospective observational study. Diabetes research and clinical practice. 2015;108(1):120-7.
  7. Williams P, McBain H, Mulligan K, Steggall MJ. Cardiovascular disease: the effect of erectile dysfunction on adherence to cardiovascular disease medication. International Journal of Urological Nursing. 2014;8(2):54-61.
  8. Thierry A, Mourad G, Buchler M, Choukroun G, Toupance O, Kamar N, et al. Three-year outcomes in kidney transplant patients randomized to steroid-free immunosuppression or steroid withdrawal, with enteric-coated mycophenolate sodium and cyclosporine: the infinity study. Journal of transplantation. 2014;2014:171898.
  9. Penfornis A, Blickle JF, Fiquet B, Quere S, Dejager S. How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study. Vascular health and risk management. 2014;10:341-52.
  10. Thierry A, Mourad G, Buchler M, Kamar N, Villemain F, Heng AE, et al. Steroid avoidance with early intensified dosing of enteric-coated mycophenolate sodium: a randomized multicentre trial in kidney transplant recipients. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2012;27(9):3651-9.
  11. Kamar N, Rostaing L, Cassuto E, Villemain F, Moal MC, Ladriere M, et al. A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients. Clinical nephrology. 2012;77(2):126-36.
  12. Humphrey L, Arbuckle R, Moldwin R, Nordling J, van de Merwe JP, Meunier J, et al. The bladder pain/interstitial cystitis symptom score: development, validation, and identification of a cut score. Eur Urol. 2012;61(2):271-9.
  13. Humphrey L, Arbuckle R, Moldwin R, Nordling J, van de Merwe JP, Meunier J, et al. Reply from Authors re: Antonella Giannantoni. Patient Reported Outcomes in Bladder Pain Syndrome: Qui Auget Dolorem, Auget et Scientiam (As Pain Increases, So Increases Knowledge). Eur Urol. 2012;61(2):282-3.
  14. Albano L, Alamartine E, Toupance O, Moulin B, Merville P, Rerolle JP, et al. Conversion from everolimus with low-exposure cyclosporine to everolimus with mycophenolate sodium maintenance therapy in kidney transplant recipients: a randomized, open-label multicenter study. Annals of transplantation. 2012;17(1):58-67.
  15. Dantal J, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, et al. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transplant international : official journal of the European Society for Organ Transplantation. 2010;23(11):1084-93.
  16. DiBenedetti DB, Gondek K, Sagnier PP, Kubin M, Marquis P, Keininger D, et al. The treatment satisfaction scale: a multidimensional instrument for the assessment of treatment satisfaction for erectile dysfunction patients and their partners. Eur Urol. 2005;48(3):503-11.
  17. Marquis P. Quality of life assessment in neurogenic bladder. In: Corcos J, Schick E, editors. Textbook of Neurogenic Bladder: Adults and Children. London: Martin Dunitz Ltd; 2004. p. 365-72.
  18. Marquis P, Marrel A. Reproducibility and clinical and concurrent validity of the MSF-4: a four-item male sexual function questionnaire for patients with benign prostatic hyperplasia. Value Health. 2001;4(4):335-43.
  19. Wool C, Cerutti R, Marquis P, Cialdella P, Hervie C. Psychometric validation of two Italian quality of life questionnaires in menopausal women. Maturitas. 2000;35(2):129-42.
  20. Richard F, Haab F, Gattegno B, Amarenco G, Ballanger P, Buzelin J-M, et al. Development and validation of a new specific questionnaire to assess women health related quality of life in urinary incontinence. XIV European Association Urology; Stockholm, Sweden, 1999.
  21. Patrick DL, Martin ML, Bushnell DM, Marquis P, Andrejasich CM, Buesching DP. Cultural adaptation of a quality-of-life measure for urinary incontinence. Eur Urol. 1999;36(5):427-35.
  22. Marquis P, Lademacher C, Rozenbaum H. Once a week transdermal estrogen -quality of life improvement in long-term replacement therapy: newest findings. In: Paoletti R, Crosignani PG, Kenemans P, Samsioe G, Soma M, Jackson AS, editors. Women’s Health and Menopause: Risk Reduction Strategies -Improved Quality of Health: Kluwer Academic Publishers; 1999. p. 183-8.
  23. Amarenco G, Marquis P, McCarthy C, Richard F. [Quality of life of women with stress urinary incontinence with or without pollakiuria]. Presse Med. 1998;27(1):5-10.
  24. Amarenco G, Marquis P, Jacquetin B, Richard F. Evaluation de la perturbation de la qualité de vie au cours des hyperactivités vésicales. Evaluation de l’hyperactivité. Paris: Elsevier; 1998. p. 61-6.
  25. Marquis P, Amarenco G, Sapede C, Josserand F, McCarthy C, Zerbib M, et al. [Elaboration and validation of a specific quality of life questionnaire for urination urgency in women]. Prog Urol. 1997;7(1):56-63.
  26. Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. Eur Urol. 1997;31(3):272-80.
  27. Amarenco G, Jacquetin B, Marquis P, Richard F. Development and validation of a disease specific quality of life questionnaire for urinary urge incontinence. International Continence Society; Sydney, Australia, 1995.
  1. Christopher-Stine L, Ciesluk A, Chinoy H, Goyal NA, Gunter K, Isenberg D, et al. The Dermatomyositis Disease Symptom Questionnaire (DM-DSQ): A Measure to Assess the Patient Experience of Dermatomyositis Symptoms. J Rheumatol. 2024:1137.
  2. Lumry WR, Maurer M, Weller K, Riedl MA, Watt M, Yu M, et al. Long-term lanadelumab treatment improves health-related quality of life in patients with hereditary angioedema. Annals of Allergy, Asthma & Immunology. 2023;131(1):101-8.e3.
  3. Watt M, Devercelli G, Lumry WR, Maurer M, Weller K, Riedl MA, et al. Sustained Improvement in Health-Related Quality of Life With Continued Lanadelumab Treatment in Hereditary Angioedema. American College of Allergy, Asthma & Immunology Annual Scientific Meeting; Louisville, KY, USA2022.
  4. Watt M, Maurer M, Devercelli G, Paes K, Regnault A, Meunier J, et al. Long-term Impact of Lanadelumab on Patients With Hereditary Angioedema (HAE) Type 1/2: Patient-Reported Outcome (PRO). Findings From the HELP Open-label Extension Study (OLE). American Academy of Asthma, Allergy & Immunology Virtual Annual Meeting; 2021 2021.
  5. Watt M, Maurer M, Devercelli G, Paes K, Regnault A, Meunier J, et al. Long-term Impact of Lanadelumab on Patients with Hereditary Angioedema (HAE) Type 1/2: Patient Reported Outcome (PRO) Findings from the HELP Open-label Extension Study (OLE). Journal of Allergy and Clinical Immunology. 2021;147(2):AB24.
  6. Morel T, Cano S, Bartlett SJ, Gordon C, Haier B, Regnault A, et al. The FATIGUE-PRO: A New Patient-Reported Outcome Instrument to Quantify Fatigue in Patients Affected by Systemic Lupus Erythematosus. Rheumatology (Oxford). 2021.
  7. Cleanthous S, Strzok S, Haier B, Cano S, Morel T. The Patient Experience of Fatigue in Systemic Lupus Erythematosus: A Conceptual Model. Rheumatol Ther. 2021.
  8. Cleanthous S, Strzok S, Haier B, Cano S, Morel T. Correction to: The Patient Experience of Fatigue in Systemic Lupus Erythematosus: A Conceptual Model. Rheumatol Ther. 2021.
  9. Cleanthous S, Bongardt S, Marquis P, Stach C, Cano S, Morel T. Psychometric Analysis from EMBODY1 and 2 Clinical Trials to Help Select Suitable Fatigue PRO Scales for Future Systemic Lupus Erythematosus Studies. Rheumatol Ther. Sep 2021;8(3):1287-1301.
  10. Lumry WR, Maurer M, Magerl M, et al. Long-Term Lanadelumab Treatment Improves Health-Related Quality of Life: HELP Open-label Extension Study Interim Findings. ACM Nexus; 2020.
  11. Cleanthous S, Regnault A, Haier B, Stach C, Cano S, Morel T. Mixed methods psychometrics program for the development of a measure of fatigue in SLE. ISOQOL; San Diego, CA, USA, 2019.
  12. Cleanthous S, Regnault A, Schneider M, Gordon C, Bartlett S, Cano S, et al. Measuring what matters to lupus patients: translating patient views into novel patient-reported outcomes. EULAR; Amsterdam, The Netherlands, 2018.
  13. Kone-Paut I, Quartier P, Fain O, Grateau G, Pillet P, Le Blay P, et al. Real-World Experience and Impact of Canakinumab in Cryopyrin-Associated Periodic Syndrome: Results From a French Observational Study. Arthritis care & research. 2017;69(6):903-11.
  14. Cleanthous S, Isenberg DA, Newman SP, Cano SJ. Patient Uncertainty Questionnaire-Rheumatology (PUQ-R): development and validation of a new patient-reported outcome instrument for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in a mixed methods study. Health and Quality of Life Outcomes. 2016;14(1):33.
  15. Strand V, Merrill J, Nikai E, Kilgallen B, Regnault A, Gordon C. Sustained Improvements in Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus Following Epratuzumab Treatment: Results from a Phase IIb Study and its Open-Label Extension. ISPOR; Montreal, Canada, 2014.
  16. Strand V, Merrill J, Nikai E, Kilgallen B, Regnault A, Gordon C. Sustained Improvements in Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus Following Epratuzumab Treatment: Results from a Phase IIb Study and its Open-Label Extension. European Lupus Meeting; Athens, Greece, 2014.
  17. Cleanthous S, Cano S, Isenberg D, Newman S. Is patient uncertainty associated with outcomes in Systemic Lupus Erythematosus? Rheumatology; Liverpool, UK, 2014.
  18. Strand V, Merrill J, Nikai E, Kilgallen B, Regnault A, Gordon C. Sustained Improvements in Health-related Quality of LiEpratuzumab treament: Results from EMBLEM™ and its Open-Label Extension Study. American College of Rheumatology (ACR); San Diego, USA, 2013.
  19. Cleanthous S, Newman SP, Shipley M, Isenberg DA, Cano SJ. What constitutes uncertainty in systemic lupus erythematosus and rheumatoid arthritis? Psychology & Health. 2013;28(2):171-88.
  20. Cleanthous S, Newman SP, Isenberg DA, Cano S. Development and validation of a new patient reported instrument of uncertainty in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). ISOQOL; 2013; Miami, USA
  21. Cleanthous S, Tyagi M, Isenberg DA, Newman SP. What do we know about self-reported fatigue in systemic lupus erythematosus? . European League Against Rheumatism Annual Congress; Berlin, Germany, 2012.
  22. Cleanthous S, Tyagi M, Isenberg D, Newman S. What do we know about self-reported fatigue in systemic lupus erythematosus? Lupus. 2012;21:465-76.
  23. Cleanthous S, Newman S, Shipley M, Ehrenstein MR, Isenberg D, Cano S. Uncertainty in Systemic Lupus Erythematosus (SLE): Development of a Conceptual Model. ISOQOL; London, UK, 2010.
  24. Cleanthous S, Cooke D, Hirani S, Kirk A, Isenberg A, Newman S. Systemic Lupus Erythematosus: Concordance and Accuracy of Patient and Physician Expectations of Physical Functioning. British Society for Rheumatology Annual Conference; Glasgow, UK, 2009.
  25. Cleanthous S, Cooke D, Kirk A, Isenberg D, Newman S. Illness perception questionnaire: An investigation of the structure of illness perceptions in systemic lupus erythematosus. Psychology & Health. 2008;23:87-88.
  26. Cleanthous S, Cooke D, Kirk A, Isenberg A, Newman S. Illness Perceptions Questionnaire: An Investigation of the Stability and Structure of Illness Representations in Systemic Lupus Erythematosus. BPS Division of Health Psychology Annual Conference; Bath, UK, 2008.
  27. Cleanthous S, Cooke D, Kirk A, Isenberg DA, Newman SP. Illness Perceptions Questionnaire: An Investigation of the Stability and Structure of Illness Representations in Systemic Lupus Erythematosus. The Pan-Hellenic Conference of Clinical and Health Psychology; 2007; Thessaloniki, Greece.
  1. Rofail D, Somersan-Karakaya S, Choi JY, Przydzial K, Zhao Y, Hussein M, et al. Thematic analysis to explore patients’ experiences with long COVID-19: a conceptual model of symptoms and impacts on daily lives. BMJ Open. 2024;14(1):e076992.
  2. Rofail D, McGale N, Podolanczuk AJ, Rams A, Przydzial K, Sivapalasingam S, et al. Patient experience of symptoms and impacts of COVID-19: a qualitative investigation with symptomatic outpatients. BMJ Open. 2022;12(5):e055989.
  3. Rofail D, McGale N, Im J, Rams A, Przydzial K, Mastey V, et al. Development and content validation of the Symptoms Evolution of COVID-19: a patient-reported electronic daily diary in clinical and real-world studies. Journal of Patient-Reported Outcomes. 2022;6(1):41.
  4. Rofail D, McGale N, Podolanczuk AJ, Rams A, Przydzial K, Sivapalasingam S, et al. The patient experience of COVID-19: A qualitative investigation with symptomatic outpatients. medRxiv; 2021.
  5. Markowitz JT, Knoble NB, Arnould B, Wu AW. Development of a contemporary symptom diary for patients with HIV. Annual Meeting of HIV; Glasgow, UK, 2016.
  6. Diez Domingo J, Patrzalek M, Cantarutti L, Arnould B, Meunier J, Soriano-Gabarro M, et al. The impact of childhood acute rotavirus gastroenteritis on the parents' quality of life: prospective observational study in European primary care medical practices. BMC Pediatr. 2012;12:58.
  7. Reygrobellet C, Viala-Danten M, Meunier J, Weber F, Nguyen VH. Perception and acceptance of intradermal influenza vaccination: Patient reported outcomes from phase 3 clinical trials. Hum Vaccin. 2010;6(4):336-45.
  8. Regnault A, Marfatia S, Louie M, Mear I, Meunier J, Viala-Danten M. Satisfactory cross-cultural validity of the ACTG symptom distress module in HIV-1-infected antiretroviral-naive patients. Clin Trials. 2009;6(6):574-84.
  9. Meunier J, Reygrobellet C, Weber F, Nguyen VH, Viala-Danten M. Perception and acceptance of intradermal influenza vaccine measured by the Vaccinees' Perception of Injection (VAPI©) questionnaire. ISPOR; Paris, France, 2009.
  10. Viala-Danten M, Meunier J, Arnould B. Development and psychometric validation of a new questionnaire measuring the impact of child gastroenteritis on parents. ISPOR; Athens, Greece, 2008.
  11. Regnault A, Marfatia S, Louie M, Viala-Danten M. Assessment of the Cross-Cultural Validity of the ACTG Symptoms Distress Module in an International HIV Clinical Trial. ISPOR; Toronto, Canada, 2008.
  1. Klassen AF, van Haren E, van Alphen TC, et al. International study to develop the WOUND-Q patient-reported outcome measure for all types of chronic wounds. Int Wound J. 2021.
  2. Costa P, Perrouin-Verbe B, Colvez A, Didier J, Marquis P, Marrel A, et al. Quality of life in spinal cord injury patients with urinary difficulties. Development and validation of qualiveen. Eur Urol. 2001;39(1):107-13.
  1. Meunier J, Oberdhan D, M'Hari M, Creel K, Adams J, Adler L. Measurement porperties and clinically meaningful change of the adult ADHD investigator symptom rating scale (AISRS). The American Professional Society of ADHD and Related Disorders (APSARD); 2022 January 13-16; Virtual.
  2. Smith SC, Hendriks AAJ, Cano SJ, Black N. Proxy reporting of health-related quality of life for people with dementia: a psychometric solution. Health Qual Life Outcomes. 2020;18(1):148.
  3. Markowitz JT, Oberdhan D, Ciesluk A, Rams A, Wigal SB. Review of Clinical Outcome Assessments in Pediatric Attention-Deficit/Hyperactivity Disorder. Neuropsychiatric Disease and Treatment. 2020;16:1619-1643.
  4. Elliott E, Green C, Llewellyn DJ, Quinn TJ. Accuracy of Telephone-Based Cognitive Screening Tests: Systematic Review and Meta-Analysis. Curr Alzheimer Res. 2020;17(5):460-471.
  5. Drozdowska BA, Elliott E, Taylor-Rowan M, et al. Cardiovascular risk factors indirectly affect acute post-stroke cognition through stroke severity and prior cognitive impairment: a moderated mediation analysis. Alzheimer's Research & Therapy. 2020;12(1):85.
  6. Calil V, Elliott E, Borelli WV, et al. Challenges in the diagnosis of dementia: insights from the United Kingdom-Brazil Dementia Workshop. Dementia & Neuropsychologia. 2020;14:201-208.
  7. McDicken JA, Elliott E, Blayney G, et al. Accuracy of the short-form Montreal Cognitive Assessment: Systematic review and validation. Int J Geriatr Psychiatry. 2019;34(10):1515-1525.
  8. Elliott E, Haldane D, Quinn TJ. Pitfalls of neurocognitive testing in an occupational medical setting. Occup Med (Lond). 2019;69(2):83-85.
  9. Cleanthous S, Barbic SP, Smith S, Regnault A. Psychometric performance of the PROMIS(R) depression item bank: a comparison of the 28- and 51-item versions using Rasch measurement theory. J Patient Rep Outcomes. 2019;3(1):47.
  10. Barbic SP, Cano SJ, Mathias S. The Problem of Patient-Centred Outcome Measurement in Psychiatry: why metrology hasn’t mattered and why it should. Journal of Physics: Conference Series. 2018;1044(1):012069.
  11. Hendriks AAJ, Smith SC, Chrysanthaki T, Cano SJ, Black N. DEMQOL and DEMQOL-Proxy: a Rasch analysis. Health Qual Life Outcomes. 2017;15(1):164.
  12. Young-Hyman DL, Peterson CM, Fischer S, Markowitz JT, Muir AB, Laffel LM. Depressive Symptoms, Emotion Dysregulation, and Bulimic Symptoms in Youth With Type 1 Diabetes: Varying Interactions at Diagnosis and During Transition to Insulin Pump Therapy. J Diabetes Sci Technol. 2016;10(4):845-51.
  13. Rofail D, Regnault A, le Scouiller S, Lambert J, Zarit SH. Assessing the impact on caregivers of patients with schizophrenia: psychometric validation of the Schizophrenia Caregiver Questionnaire (SCQ). BMC Psychiatry. 2016;16:245.
  14. Rofail D, Regnault A, le Scouiller S, Berardo CG, Umbricht D, Fitzpatrick R. Health-related quality of life in patients with prominent negative symptoms: results from a multicenter randomized Phase II trial on bitopertin. Qual Life Res. 2016;25(1):201-11.
  15. Le Scouiller S, Edgar C, Rylands A, Giroudet C, Regnault A, Zarit S, et al. Cross-cultural adaptation of the Zarit Caregiver Interview for Alzheimer's disease (ZCI-AD) and the Caregiver Global Impression Scales in 13 languages. ISPOR; Vienna, Austria, 2016.
  16. Barbic SP, Cano SJ. The application of Rasch measurement theory to psychiatric clinical outcomes research: Commentary on ... Screening for depression in primary care. BJPsych Bull. 2016;40(5):243-4.
  17. Smith SC, Hendriks AAJ, Chrysanthaki T, Cano S, Black NA. Improving the measurement of HRQL in dementia: a Rasch measurement theory approach. ISOQOL; 2015; Vancouver, Canada
  18. Smith SC, Hendriks AAJ, Chrysanthaki T, Cano S, Black N. How can we interpret proxy reports of HRQL when it is no longer possible to obtain a self-report from people with dementia? ISOQOL; 2015; Vancouver, Canada
  19. Rofail D, Acquadro C, Izquierdo C, Regnault A, Zarit SH. Cross-cultural adaptation of the Schizophrenia Caregiver Questionnaire (SCQ) and the Caregiver Global Impression (CaGI) Scales in 11 languages. Health Qual Life Outcomes. 2015;13:76.
  20. McGale N, McArdle S, Gaffney P. The effectiveness of a combined exercise and internet delivered CBT intervention for young men’s mental health. British Psychological Society Division of Health Psychology Annual Conference; London, UK, 2015.
  21. Rofail D, Regnault A, le Scoullier S, Galani Berardo C, Umbricht D, Fitzpatrick R. Health-related quality of life in people with prominent negative symptoms: results form a multi-center randomised phase II trial on bitopertin. American Psychiatric Association 167th Annual Meeting; New York, NY, USA, 2014.
  22. Posner HB, Cano S, Carrillo MC, Selnes O, Stern Y, Thomas RG, et al. Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: a new approach. Alzheimer's & dementia. 2013;9(1 Suppl):S56-60.
  23. McArdle S, McGale N, Gaffney P. A Qualitative Exploration of Men's Experiences of an Integrated Exercise/CBT Mental Health Promotion Programme. International Journal of Men's Health. 2012;11(3):240-57.
  24. McGale N, McArdle S, Gaffney P. Exploring the effectiveness of an integrated exercise/CBT intervention for young men's mental health. British journal of health psychology. 2011;16(3):457-71.
  25. McArdle S, McGale N, Gaffney P. Developing an integrated exercise/ CBT interventions for young men’s mental health: Steps in the process and process evaluations 13th European Congress of Sport Psychology: Human Performance, well-being and health; Madeira Islands, Portugal, 2011.
  26. Gaffney P, McGale N, McArdle S. Football, Life & Death: Can the beautiful game help us when addressing mental health issues in young people? British Psychological Society Northern Ireland Branch Annual Conference; Northern Ireland, UK, 2011.
  1. Markowitz JT, Rofail D, Vandenberg G, Baldasaro J, Sanchez RJ, Pignolo RJ, et al. “I Can’t Take off My Shirt or Do My Own Hair”—A Qualitative Investigation of the Symptoms and Impact Experience of Children and Adolescents with Fibrodysplasia Ossificans Progressiva (FOP). Adv Ther. 2022;39(6):2796-805.
  2. Pompilus F, Ciesluk A, Strzok S, et al. Development and psychometric evaluation of the assessment of self-injection questionnaire: an adaptation of the self-injection assessment questionnaire. Health and Quality of Life Outcomes. 2020;18(1):355.
  3. Sierakowski K, Dean NR, Pusic AL, Cano SJ, Griffin PA, Bain GI, et al. International multiphase mixed methods study protocol to develop a cross-cultural patient-reported outcome and experience measure for hand conditions (HAND-Q). BMJ Open. 2019;9(3):e025822.
  4. Meunier J, Fautrel B, Roquelaure Y, Claudepierre P. Work-related discussions between French rheumatologists and their rheumatoid arthritis patients. Occupational Medicine. 2016;66(6):454-9.
  5. Cleanthous S, Isenberg DA, Newman SP, Cano SJ. Patient Uncertainty Questionnaire-Rheumatology (PUQ-R): development and validation of a new patient-reported outcome instrument for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in a mixed methods study. Health and Quality of Life Outcomes. 2016;14(1):33.
  6. Dwek M, McBain H, Cleanthous S, Shipley M, Newman SP. Osteoarthritis: Patient Expectations about Future Pain, Stiffness and Function. Musculoskeletal Care. 2015;13(2):84-92.
  7. McBain H, Cleanthous S, Newman S. Psychological aspects of rheumatic disease. In: Watts RA, Conaghan, P., Denton, C., Foster, H., Isaacs, J., Müller-Ladner, U editor. Oxford Textbook of Rheumatology. 4th ed. Oxford: Oxford University Press; 2013.
  8. Cleanthous S, Newman SP, Shipley M, Isenberg DA, Cano SJ. What constitutes uncertainty in systemic lupus erythematosus and rheumatoid arthritis? Psychology & Health. 2013;28(2):171-88.
  9. Cleanthous S, Newman SP, Isenberg DA, Cano S. Development and validation of a new patient reported instrument of uncertainty in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). ISOQOL; 2013; Miami, USA
  10. Breuil V, Cortet B, Cotte FE, Arnould B, Dias-Barbosa C, Gaudin AF, Regnault A, et al. Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women. Osteoporos Int. 2012;23(2):445-55.
  11. Cleanthous S, Newman S, Shipley M, Isenberg D, Cano S. Developing an Understanding of Patient Uncertainty in Rheumatic Conditions. European Health Psychology Society Annual Congress; Crete, 2011.
  12. Cleanthous S, Newman S, Shipley M, Isenberg D, Cano S. Developing an Understanding of Patient Uncertainty in Rheumatic Conditions: The views of Health Care Professionals and Patients in a Qualitative Study. European League Against Rheumatism Annual Congress; London, UK, 2011.
  13. Cleanthous S, Newman S, Shipley M, Ehrenstein MR, Isenberg D, Cano S. Exploring Patient Uncertainty in Rheumatic Conditions: Comparing the views of health care professionals and patients in a qualitative design. British Society for Rheumatology Annual Conference; Brighton, UK, 2011.
  14. Regnault A, Arnould B, Cortet B, Legrand E, Breuil V, Gaudin AF, et al. Prediction of treatment discontinuation of osteoporotic patients using ADEOS score. European League against Rheumatism (EULAR) congress; 2010; Rome, Italy.
  15. Cleanthous S, Newman SP, Shipley M, Ehrenstein MR, Isenberg DA, Cano S. Evidence-based management of uncertainty in rheumatic conditions: Comparing views of health care professionals and patients. ISOQOL; 2010; London, UK
  16. Meunier PJ, Roux C, Ortolani S, Diaz-Curiel M, Compston J, Marquis P, et al. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int. 2009;20(10):1663-73.
  17. Legrand E, Breuil V, Cortet B, Roborel de Climens A, Dias-Barbosa C, Regnault A, et al. Développement et validation du questionnaire «Adhésion et Ostéoporose» (ADEOS), un instrument d'évaluation de l'adhésion des patientes au traitement de l'ostéoporose utilisable en pratique médicale courante. 22e congrès de la Société Française de Rhumatologie; 2009; Paris, France.
  18. Cortet B, Legrand E, Breuil V, Regnault A, Dias-Barbosa C, Roborel de Climens A, et al. Item reduction and validation of a new adherence questionnaire in osteoporotic post-menopausal women: the ADherence Evaluation of OSteoporosis treatment (ADEOS) questionnaire. ISPOR; Paris, France, 2009.
  19. Breuil V, Cortet B, Legrand E, Regnault A, Meunier J, Arnould B, et al. Le renouvellement des prescriptions, le jugement du médecin, les déclarations des patientes: trois perspectives complémentaires pour l'évaluation de l'adhésion des patientes pour leur traitement de l'ostéoporose. 22e congrès de la Société Française de Rhumatologie (SFR); Paris, France, 2009.
  20. Breuil V, Cortet B, Legrand E, Regnault A, Dias-Barbosa C, Arnould B, et al. Development and content validation of a new adherence questionnaire in osteoporotic post-menopausal women: ADherence Evaluation of OSteoporosis treatment (ADEOS) questionnaire. 31st annual meeting of the American Society for Bone and Mineral Research; Denver, CO, USA, 2009.
  21. Marquis P, Roux C, de la Loge C, Diaz-Curiel M, Cormier C, Isaia G, et al. Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis. Osteoporos Int. 2008;19(4):503-10.
  22. de la Loge C, Sullivan K, Pinkney R, Marquis P, Roux C, Meunier PJ. Cross-cultural validation and analysis of responsiveness of the QUALIOST: QUAlity of Life questionnaire In OSTeoporosis. Health Qual Life Outcomes. 2005;3:69.
  23. Marquis P, Cialdella P, De la Loge C. Development and validation of a specific quality of life module in post-menopausal women with osteoporosis: the QUALIOST. Qual Life Res. 2001;10(6):555-66.
  1. Markowitz JT, Mazerolle F, Lovell T, Hess LM, Abada PB, Regnault A, et al. Mixed-methods research to support the use of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library. Journal of Patient-Reported Outcomes. 2024;8(1):8.
  2. Zeidner JF, Mazerolle F, Norton J, Regnault A, Kristo F, Romero H, et al. Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes. Haematologica. 2023;108(4):1196-9.
  3. Sekeres M, Santini V, Díez-Campelo M, Komrokji R, Fenaux P, Savona M, et al. MDS-604 Improvement of Patient-Reported Fatigue in IMerge Phase 3 Trial of Imetelstat vs Placebo in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents. 2023/09/01/2023. p. S373-S4.
  4. Sekeres M, Santini V, Díez Campelo M, S. Komrokji R, Fenaux P, Robert Savona M, et al. P732: ANALYSIS OF PATIENT-REPORTED FATIGUE IN IMERGE PH3 TRIAL OF IMETELSTAT VS PLACEBO IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES R/R TO ERYTHROPOIESIS STIMULATING AGENTS. 2023/08//2023. p. e5903029.
  5. Regnault A, Loubert A, Gorsh B, Davis R, Cardellino A, Creel K, et al. A toolbox of different approaches to analyze and present PRO-CTCAE data in oncology studies. JNCI: Journal of the National Cancer Institute. 2023;115(5):586-96.
  6. Popat R, Lonial S, Voorhees PM, Esposti SD, Gorsh B, Gupta I, et al. Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma. J Adv Pract Oncol. 2023;14(6):503-18.
  7. Mikkael S, Valeria S, María Díez C, Rami SK, Pierre F, Michael Robert S, et al., editors. ANALYSIS OF PATIENT-REPORTED FATIGUE IN IMERGE PH3 TRIAL OF IMETELSTAT VS PLACEBO IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES R/R TO ERYTHROPOIESIS STIMULATING AGENTS. European Hematology Association 2023; 2023 2023.
  8. Mesa RA, Palandri F, Verstovsek S, Masarova L, Harrison C, Mazerolle F, et al. Impact of transfusion burden on health-related quality of life (HRQOL) and functioning in patients (pts) with myelofibrosis (MF): Post hoc analysis of SIMPLIFY-1 (S1) and -2 (S2). JCO. 2023;41(16_suppl):7066-.
  9. Mesa R, Palandri F, Verstovsek S, Masarova L, Harrison C, Mazerolle F, et al. PB2184: IMPACT OF TRANSFUSION BURDEN ON HEALTH-RELATED QUALITY OF LIFE AND FUNCTIONING IN PATIENTS WITH MYELOFIBROSIS: POST HOC ANALYSIS OF SIMPLIFY-1 AND -2. Hemasphere. 2023;7(S3):e3210233.
  10. Mesa R, Palandri F, Verstovsek S, Masarova L, Harrison C, Mazerolle F, et al. MPN-093 Impact of Transfusion Burden on Health-Related Quality of Life and Functioning in Patients With Myelofibrosis: Post Hoc Analysis of SIMPLIFY-1 and -2. Clinical Lymphoma Myeloma and Leukemia. 2023;23:S382.
  11. Loubert A, Creel K, Hess L, Regnault A, Payakachat N, editors. Psychometric Evaluation of Customized Lymphoma-Specific Symptom Measures Using the EORTC QLQ-C30 and Item Library: Data from a Phase 1/2 Clinical Trial of Pirtobrutinib2023 2023.
  12. Liu L, Choi J, Musoro JZ, Sauerbrei W, Amdal CD, Alanya A, et al. Single-arm studies involving patient-reported outcome data in oncology: a literature review on current practice. The Lancet Oncology. 2023;24(5):e197-e206.
  13. Kaur MN, Chan S, Bordeleau L, Zhong T, Tsangaris E, Pusic AL, et al. Re-examining content validity of the BREAST-Q more than a decade later to determine relevance and comprehensiveness. Journal of Patient-Reported Outcomes. 2023;7(1):37.
  14. Cohen J, Roeker L, Cheah C, Eyre T, Patel K, Woyach J, et al., editors. P1112 PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STUDY2023 2023.
  15. Barrett L, Elliott E, Voorhaar M, Ingelgård A, Griebsch I, Wong B, et al. A Mixed-Methods Study to Better Measure Patient-Reported Pain and Fatigue in Soft Tissue Sarcoma. Oncology and Therapy. 2023;11(1):129-43.
  16. Altman DE, Zhang X, Fu A-C, Rams AR, Baldasaro JA, Ahmad SA, et al. Development of a Conceptual Model of the Patient Experience in Small Cell Lung Cancer: A Qualitative Interview Study. Oncology and Therapy. 2023;11(2):231-44.
  17. McGregor B, O'Donnell PH, Balar A, Petrylak D, Rosenberg J, Yu EY, et al. Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial. European Urology. 2022;81(5):515-22.
  18. Ciesluk A, Voorhaar M, Barrett L, Baldasaro J, Griebsch I, Marquis P. Measuring the Patient Experience in Rare Disorders: Benefit of Pragmatic Mixed-Methods Research in NUT Carcinoma. Oncology and Therapy. 2022;10(1):263-77.
  19. Voorhaar M, Griebsch I, Pompilus F, Ciesluk A, Levine A, Baldasaro J, et al., editors. Conceptual Framework of Symptoms and Impacts Experienced By Patients with Nut Carcinoma. ISPOR; 2021 2021; Virtual.
  20. Regnault A, Quéré S, Gorsh B, Sapra S, Loubert A, Davis R, et al. Landscape review of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in oncology: Adoption and recent learnings. JCO. 2021;39(15_suppl):e18587-e.
  21. Regnault A, Quéré S, Gorsh B, Sapra S, Loubert A, Davis R, et al., editors. Landscape review of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in oncology: Adoption and recent learnings. ASCO Annual meeting; 2021.
  22. Regnault A, Pompilus F, Ciesluk A, et al. Measuring patient-reported physical functioning and fatigue in myelodysplastic syndromes using a modular approach based on EORTC QLQ-C30. Journal of Patient-Reported Outcomes. 2021;5(1):1-10.
  23. Regnault A, Loubert A, Davis R, Gorsh B, Quere S, Nelsen L, et al. Statistical analysis of symptomatic adverse events over the course of oncology clinical trials: What are the appropriate methods for longitudinal PRO-CTCAE data? ISOQOL; 2021 2021/10/12/28.
  24. Popat R, Lonial S, Voorhees PM, Degli Esposti S, Gupta I, Opalinska J, et al., editors. DREAMM-2: Single- Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). ASH; 2021 2021.
  25. Pompilus F, Ciesluk A, Marquis P, Griebsch I, Voorhaar M. Understanding the Patient Experience in NUT Carcinoma: Qualitative Interviews with Patients and Caregivers to Develop a Conceptual Framework. Oncol Ther. Aug 6 2021.
  26. Klassen AF, Kaur MN, Tsangaris E, et al. ASO Visual Abstract: Development and Psychometric Validation of BREAST-Q Scales Measuring Cancer Worry, Fatigue, and Impact on Work. Annals of surgical oncology. May 27 2021.
  27. Klassen AF, Kaur MN, Tsangaris E, et al. Development and Psychometric Validation of BREAST-Q Scales Measuring Cancer Worry, Fatigue, and Impact on Work. Annals of surgical oncology. May 24 2021.
  28. Kaur MN, Klassen AF, Xie F, et al. An international mixed methods study to develop a new preference-based measure for women with breast cancer: the BREAST-Q Utility module. BMC women's health. 2021;21(1):8.
  29. Zeidner JF, Mazerolle F, Bell JA, et al. Randomized Phase 2 Trial of Pevonedistat Plus Azacitidine Versus Azacitidine in Higher-Risk Myelodysplastic Syndromes/Chronic Myelomonocytic Leukemia or Low-Blast Acute Myeloid Leukemia: Exploratory Analysis of Patient-Reported Outcomes. 62nd American Society of Hematology Annual Meeting; 2020.
  30. Popat R, Lonial S, Voorhees P, et al. DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). 62nd American Society of Hematology Annual Meeting; 2020.
  31. Oza AM, Lorusso D, Aghajanian C, et al. Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. J Clin Oncol. 2020:Jco1903107.
  32. Klassen AF, Dominici L, Fuzesi S, Cano SJ, et al. Development and Validation of the BREAST-Q Breast-Conserving Therapy Module. Annals of surgical oncology. 2020.
  33. Kaur M, Pusic AL, Cano SJ, et al. International phase 1 study protocol to develop a health state classification system for a preference-based measure for women with breast cancer: the BREAST-Q Utility module. BMJ Open. 2020;10(1):e034451.
  34. Eliason L, Loubert A, Gorsh B, Meunier J, Kleinman DM, Sapra SR, A. Methodology for Evaluating Meaningful Change Thresholds in Patient-Reported Outcome (PRO) Measures for Corneal Events in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Single-Agent Belantamab Mafodotin (BELAMAF). ISPOR2020.
  35. Colombo N, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma. Gynecologic Oncology. 2020.
  36. Young-Afat DA, Gibbons C, Klassen AF, Vickers AJ, Cano SJ, Pusic AL. Introducing BREAST-Q Computerized Adaptive Testing: Short and Individualized Patient-Reported Outcome Assessment following Reconstructive Breast Surgery. Plast Reconstr Surg. 2019;143(3):679-684.
  37. Regnault A, Pompilus F, Ciesluk A, Mazerolle F, Bejar R, Fram RJ, et al. Creating customized patient-reported outcome measures for rare disease clinical trials: Application of the EORTC Item Library to hematological stem cell disorders. ISOQOL; San Diego, CA, USA, 2019.
  38. Pompilus F, Bell JA, Fram RJ, Faller DV, Marquis P. Identification of the most suitable patient-reported outcome instrument for trials in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. MDS International Symposium; Copenhagen, Denmark, 2019.
  39. Lee EH, Pusic AL, Cano SJ, Klassen AF. The FACE-Q Skin Cancer Module addresses post-resection aesthetic and quality of life outcomes. British Journal of Dermatology. 2019;180(4):953-4.
  40. Cracchiolo JR, Klassen AF, Young-Afat DA, Albornoz CR, Cano SJ, Patel SG, et al. Leveraging patient-reported outcomes data to inform oncology clinical decision making: Introducing the FACE-Q Head and Neck Cancer Module. Cancer. 2019;125(6):863-72.
  41. Colombo N, Oza AM, Lorusso D, et al. Patient-Centred Outcomes in the Phase 3 Study ARIEL3 of Rucaparib Maintenance Treatment in Patients with Platinum-Sensitive, Recurrent Ovarian Carcinoma: Post Hoc Exploratory Analyses by BRCA Mutation Status and Patient Age. European Society of Gynecological Oncology 21st congress, 2019; Athens, Greece.
  42. Bell JA, Pompilus F, Ciesluk A, Mazerolle F, Scipione F, Bejar R, et al. Understanding and Measuring Fatigue in Higher-Risk Myelodysplastic Syndromes, Chronic MyelomonocyticLeukemia, and Acute Myeloid Leukemia: Mixed Methods Research. MDS International Symposium; Copenhagen, Denmark, 2019.
  43. Bell JA, Galaznik A, Pompilus F, Strzok S, Bejar R, Scipione F, et al. A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Patient Rep Outcomes. 2019;3(1):35.
  44. Bedel J, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Amenedo Gancedo M, Fong PC, O’Malley DM, Meunier J, et al. Patient-Centered Outcomes in ARIEL3, a Phase 3, Randomized, Placebo-Controlled Study of Rucaparib Maintenance Treatment in Patients with Recurrent Ovarian Carcinoma. ISPOR; New Orleans, LA, USA, 2019.
  45. Lee EH, Pusic AL, Cano SJ, Klassen AF. The FACE-Q Skin Cancer Module addresses post-resection aesthetic and quality of life outcomes. The British journal of dermatology. 2018.
  46. Lee EH, Klassen AF, Cano SJ, Nehal KS, Pusic AL. FACE-Q Skin Cancer Module for Measuring Patient-Reported Outcomes Following Facial Skin Cancer Surgery. The British journal of dermatology. 2018.
  47. Kaur M, Pusic A, Xie F, Bordeleau L, Matros E, Zhong T, et al. Development of health-state classification system for a new breast cancer-specific preference-based measure: the BREAST-Q. ISOQOL; 2018; Dublin, Ireland.
  48. Bell JA, Pompilus F, Strzok S, Galaznik A, Scipione F, Fram RJ, et al. A pragmatic patient-reported outcome strategy for rare disease clinical trials: Application of the EORTC Item Library to Myelodysplastic Syndromes. ISOQOL; 2018; Dublin, Ireland.
  49. Bell JA, Pompilus F, Galaznik A, Strzok S, Bejar R, Fram RJ, et al. Enhancing the Content of the EORTC QLQ-C30 to Maximize the Detection of Treatment Benefit in Hematological Stem Cell Disorders Using the EORTC Item Library. 60th American Society of Hematology Annual Meeting and Exposition; San Diego, CA, USA, 2018.
  50. Bell JA, Pompilus F, Christian A, Mazerolle F, Scipione F, Bejar R, et al. Assessing Patient-Reported Outcomes in People with Myelodysplastic Syndromes: Can a Customized Selection of Items from the EORTC Library Enhance the EORTC QLQ-C30? 60th American Society of Hematology Annual Meeting and Exposition; San Diego, CA, USA, 2018.
  51. Bell JA, Galaznik A, Pompilus F, Strzok S, Fram RJ, Faller DV, et al. Patient Perspectives on Symptom Experience and Impact on Health-Related Quality of Life in Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia. 60th American Society of Hematology Annual Meeting and Exposition; San Diego, CA, USA, 2018.
  52. Karagiannis T, Marquis P, Petersen J, Meyers OI, Chui SY, Campbell AK, et al. Understanding patients’ ability to function in order to inform clinical benefit in oncology studies. ISPOR; Glasgow, UK, 2017.
  53. Karagiannis T, Marquis P, Petersen J, Meyers O, Chui SY, Campbell AK, et al. Beyond survival and tumor progression: Assessing patients' (pts') function to further define clinical benefit in oncology studies. American Societey of Clinical Oncology; Chicago, ILL, USA,2017.
  54. Fuzesi S, Cano SJ, Klassen AF, Atisha D, Pusic AL. Validation of the electronic version of the BREAST-Q in the army of women study. Breast. 2017;33:44-9.
  55. Bell JA, Pompilus F, Galaznik A, Strzok S, Bejar R, Fram RJ, et al. Enhancing the Content of the EORTC QLQ-C30 to Maximize the Detection of Treatment Benefit in Hematological Stem Cell Disorders Using the EORTC Item Library. American Society of Hematology annual meeting; Atlanta, GA, USA, 2017.
  56. Bell JA, Galaznik A, Pompilus F, Strzok S, Fram RJ, Faller DV, et al. Patient Perspectives on Symptom Experience and Impact on Health-Related Quality of Life in Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia. American Society of Hematology annual meeting; Atlanta, GA, USA, 2017.
  57. Robinson DJ, Esseltine DL, Regnault A, Meunier J, Liu K, van De Velde H. The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials. Br J Haematol. 2016;174(3):368-81.
  58. Lee EH, Klassen AF, Lawson JL, Cano SJ, Scott AM, Pusic AL. Patient experiences and outcomes following facial skin cancer surgery: A qualitative study. Australas J Dermatol. 2016;57(3):e100-4.
  59. Lamarca A, Elliott E, Barriuso J, et al. Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause? Cancer Treat Rev. 2016;44:26-41.
  60. Regnault A, Ferrer L, Dinet J, Gabriel S, Pavel ME, Ruszniewski PB, et al. Health-Related Quality of Life in CLARINET, a phase III Trial of Lanreotide Autogel 120mg in Patients with Non-Functioning Entero-Pancreatic neuroendocrine Tumour: Analytical Challenges and Statistical Solutions. ISOQOL; Vancouver, Canada, 2015.
  61. Klassen AF, Rosenberg-Yunger ZR, D'Agostino NM, Cano SJ, Barr R, Syed I, et al. The development of scales to measure childhood cancer survivors' readiness for transition to long-term follow-up care as adults. Health expectations : an international journal of public participation in health care and health policy. 2015;18(6):1941-55.
  62. Klassen AF, Cano SJ, Sinha R, Shahbaz A, Klaassen R, Dix D. Is the Give Youth a Voice questionnaire an appropriate measure of teen-centred care in paediatric oncology: a Rasch measurement theory analysis. Health expectations : an international journal of public participation in health care and health policy. 2015;18(5):1686-97.
  63. Socinski MA, Butts CA, Mitchell P, Thatcher N, Scagliotti G, Robinet G, et al. Exploration of patient health status as measured by the EQ-5D questionnaire alongside the START trial of tecemotide (L-BLP25) in NSCLC. World Conference on Lung Cancer; Sydney, Australia, 2013.
  64. Pusic AL, Cemal Y, Albornoz C, Klassen A, Cano S, Sulimanoff I, et al. Quality of life among breast cancer patients with lymphedema: a systematic review of patient-reported outcome instruments and outcomes. Journal of cancer survivorship : research and practice. 2013;7(1):83-92.
  65. Lee EH, Klassen AF, Nehal KS, Cano SJ, Waters J, Pusic AL. A systematic review of patient-reported outcome instruments of nonmelanoma skin cancer in the dermatologic population. Journal of the American Academy of Dermatology. 2013;69(2):e59-67.
  66. Lee EH, Klassen A, Lawson JL, Cano SJ, Scott AM, Nehal KS, et al. A qualitative study to develop a conceptual framework to understand the health concerns of patients who undergo facial surgery for skin cancer. ISOQOL; Miami, FL, USA, 2013.
  67. Lawson JL, Scott AM, Lee EH, Matros E, Albornoz CR, Price AN, et al. Quality of life and the impact of altered facial appearance in head and neck cancer patient populations: a qualitative study. ISOQOL; 2013; Miami, FL, USA.
  68. Hoyt MA, Cano SJ, Saigal CS, Stanton AL. Health-related quality of life in young men with testicular cancer: validation of the Cancer Assessment for Young Adults (CAYA). Journal of cancer survivorship : research and practice. 2013;7(4):630-40.
  69. Albornoz CR, Pusic AL, Reavey P, Scott AM, Klassen AF, Cano SJ, et al. Measuring health-related quality of life outcomes in head and neck reconstruction. Clinics in plastic surgery. 2013;40(2):341-9.
  70. Scott AM, Ho AL, Klassen AF, Cano S, VanLaeken NY, Cordeiro P, et al. Patient-reported satisfaction with reconstructed breasts in the long-term survivorship period: Comparison of autologous and non-autologous breast reconstruction. American Society of Clinical Oncology; Chicago, IL, USA 2012.
  71. Scott AM, Ho AL, Klassen A, Cano S, VanLaeken N, Cordeiro P, et al. Patient-reported satisfaction with reconstructed breasts in the long-term survivorship period: comparison of autologous and non-autologous breast reconstruction. ISOQOL; 2012; Budapest, Hungary
  72. Pusic AL, Klassen AF, Scott AM, Cano SJ. Measuring and managing patient expectation for breast reconstruction: a new preoperative patient assessment tool. Appearance Matters 5; 2012; Bristol, UK
  73. Pusic A, Klassen A, Scott AM, Cano S, Shouery M, Basch EM. Feasibility and acceptability of patient-reported outcomes data collection for clinical care following breast reconstruction. American Society of Clinical Oncology; 2012; Chicago, IL, USA
  74. Pusic A, Cano S, Klassen A, Scott AM, Shouery M, Basch E, et al. Feasibility and acceptability of patient-reported outcomes data collection for clinical care following breast reconstruction. ISOQOL; Budapest, Hungary, 2012.
  75. Price AN, Scott AM, Klassen A, Cano S, Mehrara BJ, Disa JJ, et al. Patient-reported satisfaction with psychosocial and sexual well-being and the nipple areola complex: comparison of preservation and reconstruction. ISOQOL; Budapest, Hungary, 2012.
  76. Ho AL, Klassen A, Cano S, Scott AM, Pusic A. Optimizing satisfaction in breast reconstruction: the importance of the preoperative information and patient-physician communication. ISOQOL; Budapest, Hungary, 2012.
  77. Gilet H, Regnault A. Analysis of time to patient-reported outcome meaningful change: illustration from a clinical trial of catumaxomab in patients with malignant ascites. International Society for Clinical Biostatistics (ISCB) 33rd Annual Conference; Bergen, Norway, 2012.
  78. Delforge M, Dhawan R, Robinson DJ, Meunier J, Regnault A, Esseltine DL, et al. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. Eur J Haematol. 2012;89(1):16-27.
  79. Albornoz CR, Matros M, Pusic A, Klassen A, Cano S, McCarthy C, et al. Breast reconstruction and radiation: an analysis of quality of life and satisfaction among patients undergoing implant reconstruction. ISOQOL; 2012; Budapest, Hungary.
  80. Scott AM, Klassen AF, Pusic AL, Cano S, Cordeiro PG, Morrow M, et al. Adaptation of existing PRO measures for use in additional patient populations: The BREAST-Q© BCT Module. ISOQOL; 2011; Denver, CO, USA.
  81. Matros E, Albornoz CR, Reavey PL, Cano SJ, Klassen AF, Pusic AL. Missing elements in current head and neck patient reported outcome measures. ISOQOL; 2011; Denver, CO, USA.
  82. Gilet H, Bredart A, Regnault A, Bhandary D, Parasuraman B. An evaluation of statistical methods used to analyse patient-reported outcomes (PRO) data in published metastatic cancer studies. ISPOR; Madrid, Spain, 2011.
  83. Snell LJ, Cano SJ, Klassen AF, McCarthy CM, Scott AM, Cordeiro PG, et al. Measuring and managing patient expectation for breast reconstruction: A new preoperative patient assessment tool. ISOQOL; 2010; London, UK.
  84. Scott AM, McCarthy CM, Klassen AF, Cano SJ, Pusic AL, Jhanwar SM. Development of a new BREAST-Q module for Breast Cancer Patients: The Breast-Conserving Therapy (BCT) Module ISOQOL; London, UK, 2010.
  85. Regnault A, Gater A, Battersby C, McIntosh S, Meunier J, Abetz L. Confirmation of Brief Pain Inventory Short Form (BPI-SF) 'worst pain' item cut-point for the assessment of pain progression in castration-resistant prostate cancer (CRPC). ISPOR; Prague, Czech Republic, 2010.
  86. De Jong F, Viala-Danten M, Van Herwaarden R, Poppe K, Van Haaster C, Meunier J, et al. Psychometric validation of a patient questionnaire evaluating satisfaction with a darbepoetin alpha pre-filled device for self-injection (Aranesp® SureClick™ device), and a home-service (2care® service) in chemotherapy-induced anaemic cancer patients. ISPOR; Atlanta, USA, 2010.
  87. Cano S, Klassen AF, Scott A, Thoma A, Feeny D, Pusic A. Health outcome and economic measurement in breast cancer surgery: challenges and opportunities. Expert Rev Pharmacoecon Outcomes Res. 2010;10(5):583-94.
  88. Bredart A, Sultan S, Regnault A. Patient satisfaction instruments for cancer clinical research or practice. Expert Rev Pharmacoecon Outcomes Res. 2010;10(2):129-41.
  89. Meunier J, Regnault A, Robinson DJ, Rosa K, San Miguel JF, Richardson PG, et al. Impact of tumor response on health-related quality of life (HRQoL) in newly diagnosed multiple myeloma patients treated with VELCADE/melphalan/prednisone (V-MP): Results from the VISTA trial. ISPOR Paris, France, 2009.
  90. Klassen AF, Dix D, Cano SJ, Papsdorf M, Sung L, Klaassen RJ. Evaluating family-centred service in paediatric oncology with the measure of processes of care (MPOC-20). Child: care, health and development. 2009;35(1):16-22.
  91. Dhawan R, Robinson DJ, Meunier J, Regnault A, Rosa K, Cakana A, et al. Sustained Health-Related Quality of Life (HRQoL) improvement in newly diagnosed multiple myeloma patients treated with bortezomib/melphalan/prednisone versus melphalan/prednisone: results from the VISTA trial. American Society of Hematology annual meeting; New Orleans, USA, 2009.
  92. Dhawan R, Meunier J, Regnault A, Rosa K, Robinson DJ, Cakana A, et al. Impact of Complete Response on Health-Related Quality of Life in newly diagnosed multiple myeloma patients: results from the VISTA trial. 12th International Multiple Myeloma Workshop; Washington DC, USA, 2009.
  93. Pusic A, Liu JC, Chen CM, Cano S, Davidge K, Klassen A, et al. A systematic review of patient-reported outcome measures in head and neck cancer surgery. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2007;136(4):525-35.
  94. Pusic AL, Liu J, Chen CM, Cano S, Davridge K, Klassen A, et al. Health-Related Quality of Life in Head and Neck Cancer: A Review of Patient-Reported Outcome Measures. American Head and Neck Society Annual Meeting; Chicago, IL, USA, 2006.
  1. Regnault A, Habib AA, Creel K, Kaminski HJ, Morel T. Clinical meaningfulness and psychometric robustness of the MG Symptoms PRO scales in clinical trials in adults with myasthenia gravis. Front Neurol. 2024;15.
  2. Petrillo J, Sawant R, Elliott E, Cleanthous S, Rogers R, Cano S, et al. Rasch Measurement Theory (RMT) Analyses of the Huntington’s Disease Everyday Functioning (Hi-DEF) to Evaluate Item Fit and Performance. JHD. 2024:1-13.
  3. Meunier J, Creel K, Loubert A, Larsen KG, Aggarwal J, Hefting N, et al. Defining a clinically meaningful within-patient change threshold for the Cohen-Mansfield Agitation Inventory in Alzheimer’s dementia. Front Neurol. 2024;15:1379062.
  4. Staunton H, Cleanthous S, Teodoro V, Barrett L, Braid J, Ewens B, et al. A Mixed-method Approach to Develop an Ambulatory Module of the SMA Independence Scale. Journal of Neuromuscular Diseases. 2023;Preprint(Preprint):1-17.
  5. Regnault A, Morel T, de la Loge C, Mazerolle F, Kaminski HJ, Habib AA. Measuring Overall Severity of Myasthenia Gravis (MG): Evidence for the Added Value of the MG Symptoms PRO. Neurol Ther. 2023;12(5):1573-90.
  6. Regnault A, Meunier J, Ciesluk A, Cheng W, Zhu B. Providing meaningful interpretation of performance outcome measures by co-calibration with patient-reported outcomes through the Rasch model: illustration with multiple sclerosis measures. Journal of Biopharmaceutical Statistics. 2023;0(0):1-21.
  7. Regnault A, Loubert A, Brennan R, Meunier J, Naujoks C, Cano S, et al. Does the Multiple Sclerosis Impact Scale-29 (MSIS-29) have the range to capture the experience of fully ambulatory multiple sclerosis patients? Learnings from the ASCLEPIOS studies. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2023;9(3):20552173231201422.
  8. Ratcliffe N, Cleanthous S, Andrejack J, Barker R, Blavat G, Brooks W, et al. Plain language summary: what symptoms should be measured in clinical studies for early-stage Parkinson's? Future Neurology. 2023;18(1):FNL65.
  9. Prato M, Regnault A, Quéré S, Massat N, Benoit A, Morel T. Repurposing the MDS-UPDRS part III for early-stage Parkinson’s disease: Supportive evidence for a bradykinesia and rigidity specific sub-score. 2023 International Congress; 2023 2023.
  10. Morel T, Schroeder K, Cleanthous S, Andrejack J, Blavat G, Brooks W, et al. The value of co-creating a clinical outcome assessment strategy for clinical trial research: process and lessons learnt. Research Involvement and Engagement. 2023;9(1):98.
  11. Morel T, Cleanthous S, Andrejack J, Barker RA, Biagioni M, Blavat G, et al. Development and early qualitative evidence of two novel patient-reported outcome instruments to assess daily functioning in people with early-stage Parkinson’s. Journal of Patient-Reported Outcomes. 2023;7(1):40.
  12. Melin J, Cano SJ, Gillman A, Marquis S, Flöel A, Göschel L, et al. Traceability and comparability through crosswalks with the NeuroMET Memory Metric. Sci Rep. 2023;13(1):5179.
  13. Greene N, Quéré S, Bury DP, Mazerolle F, M’Hari M, Loubert A, et al. Establishing clinically meaningful within-individual improvement thresholds for eight patient-reported outcome measures in people with relapsing-remitting multiple sclerosis. Journal of Patient-Reported Outcomes. 2023;7(1):61.
  14. Trundell D, Skalicky A, Staunton H, et al. Development of the SMA Independence Scale–Upper Limb Module (SMAIS–ULM): A novel scale for individuals with Type 2 and non-ambulant Type 3 SMA. Journal of the Neurological Sciences. 2021:117318.
  15. Morel T, Cleanthous S, Andrejack J, Barker RA, Blavat G, Brooks W, et al. Patient Experience in Early-Stage Parkinson’s Disease: Using a Mixed Methods Analysis to Identify Which Concepts Are Cardinal for Clinical Trial Outcome Assessment. Neurol Ther. 2022;11(3):1319-40.
  16. Morel T, Cleanthous S, Andrejack J, Barker RA, Blavat G, Boroojerdi B, et al. Outcome Assessment in Early-Stage Parkinson’s Disease (PD) Clinical Trials: Are Legacy Patient-Reported Outcome (PRO) Instruments Fit for Purpose (P1-1.Virtual). Neurology. 2022;98(18 Supplement).
  17. Jivraj F, Kang S, Reedie S, Kapadia S, Strzok S, Elliott E, et al. The Patient and Clinician Assessment of Gastrointestinal (GI) Related Adverse Events Associated with Oral Disease-Modifying Therapies in Multiple Sclerosis: A Qualitative Study. Adv Ther. 2022;39(11):5072-86.
  18. Billet J, Levine A, Johannesen J, Sawant R, Lovell T, Rams A, et al. Psychometric Validation of Huntington’s Disease Everyday Functioning (Hi-DEF) Scale –Study Design and Sample Characteristics (P3-11.005). Neurology. 2022;98(18 Supplement).
  19. Billet J, Levine A, Johannesen J, Lovell T, Rams A, Gusse E, et al. Patient Experiences in early Huntington’s Disease - Qualitative Research to Inform Development of a Patient-Reported Instrument of Everyday Functioning (P3-11.003). Neurology. 2022;98(18 Supplement).
  20. Moor Cd, Elliott E, Koulinska I, Jhaveri M, Cano S, Rock M, et al. Psychometric Validation of the Instrumental and Cognitive ADL Scales: New Promising PRO Instruments for Early MS (2742). Neurology. 2021;96(15 Supplement).
  21. Klassen AF, Rae C, Gallo L, et al. Psychometric Validation of the FACE-Q Craniofacial Module for Facial Nerve Paralysis. Facial Plast Surg Aesthet Med. Apr 7 2021.
  22. de Moor C, Elliott E, Koulinska I, Jhaveri M, Cano S, Rock M, et al. Psychometric Validation of the Instrumental and Cognitive ADL Scales: New Promising PRO Instruments for Early MS (2742). American Academy of Neurology Annual meeting; 2021; Virtual.
  23. Cleanthous S, Mork AC, Regnault A, Cano S, Kaminski HJ, Morel T. Development of the Myasthenia Gravis (MG) Symptoms PRO: a case study of a patient-centred outcome measure in rare disease. Orphanet J Rare Dis. 2021;16(1):457.
  24. Regnault A, Meunier J, Ciesluk A, et al. Providing Meaningful Interpretation of a Performance Outcome Measure by Co-Calibration with a Patient-Reported Outcome: Illustration with Widely Used Multiple Sclerosis Measures. Paper presented at: ISOQOL (Cutting Edge Research plenary session)2020.
  25. Drozdowska BA, Elliott E, Taylor-Rowan M, et al. Cardiovascular risk factors indirectly affect acute post-stroke cognition through stroke severity and prior cognitive impairment: a moderated mediation analysis. Alzheimer's Research & Therapy. 2020;12(1):85.
  26. Taylor-Rowan M, Keir R, Cuthbertson G, Shaw R, Drozdowska B, Elliott E, et al. Pre-Stroke Frailty Is Independently Associated With Post-Stroke Cognition: A Cross-Sectional Study. J Int Neuropsychol Soc. 2019;25(5):501-506.
  27. Taylor-Rowan M, Cuthbertson G, Keir R, Shaw R, Drozdowska B, Elliott E, et al. The prevalence of frailty among acute stroke patients, and evaluation of method of assessment. Clinical rehabilitation. 2019;33(10):1688-1696.
  28. Shaw RC, Walker G, Elliott E, Quinn TJ. Occurrence Rate of Delirium in Acute Stroke Settings: Systematic Review and Meta-Analysis. Stroke. 2019;50(11):3028-3036.
  29. Shaw R, Drozdowska B, Taylor-Rowan M, Elliott E, et al. Delirium in an Acute Stroke Setting, Occurrence, and Risk Factors. Stroke. 2019;50(11):3265-3268.
  30. Regnault A, Boroojerdi B, Meunier J, Bani M, Morel T, Cano S. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort. Journal of neurology. 2019.
  31. Pendrill LR, Cano SJ, editors. NeuroMET Memory Metric version 0.1. IAGG-ER: International Association of Gerontology and Geriatrics for the European Region; 2019; Stockholm, Sweden.
  32. McDicken JA, Elliott E, Blayney G, et al. Accuracy of the short-form Montreal Cognitive Assessment: Systematic review and validation. Int J Geriatr Psychiatry. 2019;34(10):1515-1525.
  33. Kamunodi P, McBurney R, Schiffon W, Kolaczkowski L, Schmidt H, Santiago L, et al. Building effective patient engagement in drug development: An example based on people with MS collaborating with a pharmaceutical company. ISOQOL; 2019; San Diego, CA, USA.
  34. Fillmer A, Melin J, Pendrill L, Goschel L, Cano S, Aydin S, et al. Towards a better understanding of Alzheimer’s Disease: Rasch transformation of cognitive assessment data yields better linear description of cognition using neurometabolite concentrations as explanatory variables. International Society for Magnetic Resonance in Medicine; Montreal, Canada, 2019.
  35. Cleanthous S, Regnault A, Mork A, Cano S, Morel T. Mixed methods psychometrics for the development of patient-centered outcome measures in rare diseases: the example of myasthenia gravis symptom PROs. ISOQOL; San Diego, CA, USA, 2019.
  36. Strzok S, Cleanthous S, Pompilus F, Cano SJ, Marquis P, Cohan S, et al. Development of a gait module to complement the 12-item Multiple Sclerosis Walking Scale: a mixed methods study. Multiple Sclerosis Journal. 2018;4(2):2055217318783766.
  37. Regnault A, Boroojerdi B, Meunier J, Bani M, Cano S. A Psychometric Analysis of the MDS-UPDRS-II and -III in Early Parkinson’s Disease: Do the Numbers Add Up? International Congress of Parkinson’s Disease and Movement Disorders; October 8; Hong Kong, China, 2018.
  38. Quinn TJ, Elliott E, Langhorne P. Cognitive and Mood Assessment Tools for Use in Stroke. Stroke. 2018;49(2):483-490.
  39. Quaglia M, Belloti C, Cano S, Cryar A, Deane K, Divieto C, et al. Better measurement for improved diagnosis and management of Alzheimer’s disease: Update on the EMPIR NeuroMET project. Alzheimer's Association International Conference; Chicago, IL, USA, 2018.
  40. Cleanthous S, Strzok S, Pompilus F, Cano S, Marquis P, Cohan S, et al. Addressing the targeting range of the ABILHAND-56 in relapsing–remitting multiple sclerosis: A mixed methods psychometric study. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2018;4(2):2055217318776990.
  41. Cleanthous S, Cano SJ. Theories behind dystonia scale development. In: Dressler A, Krauss, editor. Treatment of Dystonia. Cambridge: Cambridge University Press; 2018.
  42. Petrillo J, Cadavid D, Castrillo-Viguera C, Cleanthous S, Pompilus F, Strzok S, et al. Expanding Our Understanding of Daily Life Activity Impact in Patients with Multiple Sclerosis. 7th Joint ECTRIMS-ACTRIMS Meeting; Paris, France, 2017.
  43. Hurt C, Cleanthous S, Newman SP. Further explorations of illness uncertainty: Carer's experiences of Parkinson's disease. Psychology & Health. 2017;32(5):549-66.
  44. Cleanthous S, Cano S, Kinter E, Marquis P, Petrillo J, You X, et al. Measuring the impact of multiple sclerosis: Enhancing the measurement performance of the Multiple Sclerosis Impact Scale (MSIS-29) using Rasch Measurement Theory (RMT). Multiple Sclerosis Journal – Experimental, Translational and Clinical. 2017;3(3):2055217317725917.
  45. Chen SY, Strzok S, Cleanthous S, Pompilus F, Cano S, Marquis P, et al. Development of a Gait Module to Complement the 12-item Patient-Reported Multiple Sclerosis Walking Scale. American Academy of Neurology 2017 - 69th Annual Meeting; Boston, MA, USA, 2017.
  46. Chen SY, Pompilus F, Strzok S, Cleanthous S, Cano S, Marquis P, et al. Patient-Reported Outcome Measurement in Manual Ability for Multiple Sclerosis: Addressing the Targeting Issues of the ABILHAND (P3. 364). American Academy of Neurology Boston, MA, USA, 2017.
  47. Chen SY, Pompilus F, Strzok S, Cleanthous S, Cano S, Marquis P, et al. Development of a Conceptual Framework for Daily Life Activities in Patients with Early Stage Relapsing-Remitting Multiple Sclerosis. 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; London, UK, 2016.
  48. Baker K, Barrett L, Playford ED, Aspden T, Riazi A, Hobart J. Measuring arm function early after stroke: is the DASH good enough? Journal of neurology, neurosurgery, and psychiatry. 2016;87(6):604-10.
  49. Rakusa M, Cano SJ, Porter B, Riazi A, Thompson AJ, Chataway J, et al. A predictive model for corticosteroid response in individual patients with MS relapses. PloS one. 2015;10(3):e0120829.
  50. Hobart J, Cleanthous S, Zajieck J, Cano S. CONFUSION IN CLINICAL TRIALS OF ALZHEIMER'S DISEASE. Journal of Neurology Neurosurgery & Psychiatry. 2015;86:e4.
  51. Cano S, Cleanthous S, Marquis P, Hobart J, Naoshy S, Mikol D, et al. Measuring the Impact of Multiple Sclerosis: Enhancing the Performance of the Msis-29 and Msws-12. ISPOR; Milan, Italy, 2015.
  52. Cano S, Cleanthous S, Marquis P, Hobart J, Naoshy S, Mikol D, et al. Measuring the Impact of Secondary Progressive Multiple Sclerosis (Spms) in the Ascend Trial: Equating the Msis-29, Msws-12, Abilhand-56 and Sf-36. ISPOR; Milan, Italy, 2015.
  53. Cano S, Cleanthous S, Marquis P, Hobart J, Naoshy S, Mikol D, et al. Measuring Upper Limb Function In Multiple Sclerosis: Enhancing The Abilhand’s Performance. ISPOR; Philadelphia, USA, 2015.
  54. Cano S, Cleanthous S, Kinter E, Hobart J, Marquis P, Petrillo J, et al. Measuring the impact of multiple sclerosis: enhancing the MSIS-29's performance. Congress of European Committee for Treatment and Research in Multiple Sclerosis; Barcelona, Spain, 2015.
  55. Barrett L, Cano S, Zajicek J, Hobart J. Lending a hand: can DASH items help ABILHAND improve manual ability measurement in multiple sclerosis? Multiple sclerosis (Houndmills, Basingstoke, England). 2015;21(5):612-21.
  56. Jellie B, Sweetland J, Riazi A, Cano SJ, Playford ED. Staying at work and living with MS: a qualitative study of the impact of a vocational rehabilitation intervention. Disability and rehabilitation. 2014;36(19):1594-9.
  57. Cano SJ, Mayhew A, Glanzman AM, Krosschell KJ, Swoboda KJ, Main M, et al. Rasch analysis of clinical outcome measures in spinal muscular atrophy. Muscle & nerve. 2014;49(3):422-30.
  58. van Seventer R, Vos C, Giezeman M, Meerding WJ, Arnould B, Regnault A, et al. Validation of the Dutch version of the DN4 diagnostic questionnaire for neuropathic pain. Pain Pract. 2013;13(5):390-8.
  59. Posner HB, Cano S, Carrillo MC, Selnes O, Stern Y, Thomas RG, et al. Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: a new approach. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2013;9(1 Suppl):S56-60.
  60. Mayhew AG, Cano SJ, Scott E, Eagle M, Bushby K, Manzur A, et al. Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Developmental medicine and child neurology. 2013;55(11):1046-52.
  61. Hobart J, Cano S, Posner H, Selnes O, Stern Y, Thomas R, et al. Putting the Alzheimer's cognitive test to the test II: Rasch Measurement Theory. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2013;9(1 Suppl):S10-20.
  62. Hobart J, Cano S, Posner H, Selnes O, Stern Y, Thomas R, et al. Putting the Alzheimer's cognitive test to the test I: traditional psychometric methods. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2013;9(1 Suppl):S4-9.
  63. Hobart J, Cano S, Baron R, Thompson A, Schwid S, Zajicek J, et al. Achieving valid patient-reported outcomes measurement: a lesson from fatigue in multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2013;19(13):1773-83.
  64. Barrett LE, Cano SJ, Zajicek JP, Hobart JC. Can the ABILHAND handle manual ability in MS? Multiple sclerosis (Houndmills, Basingstoke, England). 2013;19(6):806-15.
  65. Mayhew AG, Eagle M, Scott E, Bushby KMD, Adnan M, Muntoni F, et al. Trial readiness: clinical interpretability of change scores of the North Star Ambulatory Assessment in Duchenne muscular dystropy. 17th International Congress of The World Muscle Society; Perth, Australia, 2012.
  66. Hobart JC, Cano SJ, Thompson AJ, Andrich D. It's time to change the way we measure change: demonstration, explanation, recommendations. 28th Congress of the European Committee for Treatment and Research In Multiple Sclerosis; 2012; Lyon, France.
  67. Ho AL, Scott AM, Klassen AF, Cano SJ, Pusic AL, Van Laeken N. Measuring quality of life and patient satisfaction in facial paralysis patients: a systematic review of patient-reported outcome measures. Plast Reconstr Surg. 2012;130(1):91-9.
  68. Mayhew A, Cano S, Scott E, Eagle M, Bushby K, Muntoni F. Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Developmental medicine and child neurology. 2011;53(6):535-42.
  69. Cano SJ, Barrett LE, Zajicek JP, Hobart JC. Beyond the reach of traditional analyses: using Rasch to evaluate the DASH in people with multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2011;17(2):214-22.
  70. Baker K, Cano SJ, Playford ED. Outcome measurement in stroke: a scale selection strategy. Stroke. 2011;42(6):1787-94.
  71. Zajicek JP, Cano SJ, Barrett LE, Hobart JC. Beyond traditional psychometric methods: Can Rasch help the DASH? . ISOQOL; 2010; London, UK.
  72. Regnault A, Gilet H, Meerding WJ, Arnould B. Methodological challenges for the evaluation of patient-reported screening tools: Example of a neuropathic pain screening tool. 31st Annual conference of the International Society for Clinical Biostatistics (ISCB); 2010; Montpellier, France.
  73. Freeman RG, Cano S, Slade A, Delatycki M, Tai G, Hobart J. Cross-cultural Comparisons: Lessons from Friedreich's Ataxia ISOQOL; London, UK, 2010.
  74. Cano SJ, Thompson AJ. How to measure the effects of rehabilitation. In: Kesselring, Comi, Thompson, editors. Recovery in Multiple Sclerosis. Cambridge: Cambridge University Press; 2010.
  75. Cano SJ, Posner HB, Moline ML, Hurt SW, Swartz J, Hsu T, et al. The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts. Journal of neurology, neurosurgery, and psychiatry. 2010;81(12):1363-8.
  76. Baker K, Playford ED, Cano SJ. Reaching the right decision: Proposal of a scale selection strategy in stroke research. ISOQOL; 2010; London, UK.
  77. Hobart J, Cano S. Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods. Health technology assessment (Winchester, England). 2009;13(12):iii, ix-x, 1-177.
  78. Cano SJ, Riazi A, Schapira AH, Cooper JM, Hobart JC. Friedreich's ataxia impact scale: a new measure striving to provide the flexibility required by today's studies. Movement disorders : official journal of the Movement Disorder Society. 2009;24(7):984-92.
  79. Cano S, Posner H, Aisen P, Selnes O, Stern Y, Thomas R, et al. The ADAS-cog's performance as a measure—lessons from the ADNI study: Part 2 - evaluation using modern psychometric methods. 61st Alzheimer's Association International Conference on Alzheimer's Disease; Vienna, Austria, 2009.
  80. Cano SJ, Warner TT, Thompson AJ, Bhatia KP, Fitzpatrick R, Hobart JC. The cervical dystonia impact profile (CDIP-58): can a Rasch developed patient reported outcome measure satisfy traditional psychometric criteria? Health Qual Life Outcomes. 2008;6:58.
  81. Sweetland J, Riazi A, Cano SJ, Playford ED. Vocational rehabilitation services for people with multiple sclerosis: what patients want from clinicians and employers. Multiple sclerosis (Houndmills, Basingstoke, England). 2007;13(9):1183-9.
  82. Cano SJ, Warner TT. Dystonia rating scales. In: Warner TT, Bressman S, editors. Clinical Diagnosis and Management of Dystonia. Oxford: Informa Healthcare; 2007.
  83. Cano SJ, Warner TT. Dystonia and quality of life. In: Warner TT, Bressman S, editors. Clinical Diagnosis and Management of Dystonia. Oxford: Informa Healthcare; 2007.
  84. Cano SJ, Thompson AJ, Bhatia K, Fitzpatrick R, Warner TT, Hobart JC. Evidence-based guidelines for using the Short Form 36 in cervical dystonia. Movement disorders : official journal of the Movement Disorder Society. 2007;22(1):122-6.
  85. Bakheit AM, Shaw S, Barrett L, Wood J, Carrington S, Griffiths S, et al. A prospective, randomized, parallel group, controlled study of the effect of intensity of speech and language therapy on early recovery from poststroke aphasia. Clinical rehabilitation. 2007;21(10):885-94.
  86. Riazi A, Cano SJ, Cooper JM, Bradley JL, Schapira AH, Hobart JC. Coordinating outcomes measurement in ataxia research: do some widely used generic rating scales tick the boxes? Movement disorders : official journal of the Movement Disorder Society. 2006;21(9):1396-403.
  87. Cano SJ, Hobart JC, Edwards M, Fitzpatrick R, Bhatia K, Thompson AJ, et al. CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia. Neurology. 2006;67(12):2230-2.
  88. Cano SJ, Hobart JC. Measuring multiple sclerosis rehabilitation outcomes. In: Thompson AJ, editor. Neurological Rehabilitation of Multiple Sclerosis. Oxford: Informa Healthcare; 2006.
  89. O'Connor RJ, Cano SJ, Ramio i Torrenta L, Thompson AJ, Playford ED. Factors influencing work retention for people with multiple sclerosis: cross-sectional studies using qualitative and quantitative methods. Journal of neurology. 2005;252(8):892-6.
  90. Cano SJ, Hobart JC, Hart PE, Korlipara LV, Schapira AH, Cooper JM. International Cooperative Ataxia Rating Scale (ICARS): appropriate for studies of Friedreich's ataxia? Movement disorders : official journal of the Movement Disorder Society. 2005;20(12):1585-91.
  91. McNeill A, Cano S, Warner TT. Clinical diagnosis of cervical dystonia. The European journal of general practice. 2004;10(2):73-4; discussion 4.
  92. Cano SJ, Warner TT, Linacre JM, Bhatia KP, Thompson AJ, Fitzpatrick R, et al. Capturing the true burden of dystonia on patients: the Cervical Dystonia Impact Profile (CDIP-58). Neurology. 2004;63(9):1629-33.
  93. Cano SJ, Hobart JC, Fitzpatrick R, Bhatia K, Thompson AJ, Warner TT. Patient-based outcomes of cervical dystonia: a review of rating scales. Movement disorders : official journal of the Movement Disorder Society. 2004;19(9):1054-9.
  94. Cano SJ, Browne JP, Lamping DL, Roberts AH, McGrouther DA, Black NA. The Patient Outcomes of Surgery-Hand/Arm (POS-Hand/Arm): a new patient-based outcome measure. Journal of hand surgery (Edinburgh, Scotland). 2004;29(5):477-85.
  95. Bakheit AMO, Barrett L, Wood J. The relationship between the severity of post‐stroke aphasia and state self‐esteem. Aphasiology. 2004;18(8):759-64.
  96. Warner TT, Cano SJ, Fitzpatrick R, Bhatia K, Thompson AJ, Hobart JC. The Cervical Dystonia Impact Profile (CDIP-58): 1 – Development and Validation. ISOQOL; 2003; Prague, Czech Republic.
  97. Hobart JC, Cano SJ, Thompson AJ, O’Connor R. The Multiple Sclerosis Impact Scale: validation in eight European countries using Rasch technology. ISOQOL; 2003; Prague, Czech Republic.
  98. Cano SJ, Warner TT, Hobart JC. The Cervical Dystonia Impact Profile (CIDP-58): 2 – Comparison of traditional methods and Rasch technology for developing scales. ISOQOL; 2003; Prague, Czech Republic.
  1. Harrison C, Apon I, Ardouin K, Sidey-Gibbons C, Klassen A, Cano S, et al. The Development, Deployment, and Evaluation of the CLEFT-Q Computerized Adaptive Test: A Multimethods Approach Contributing to Personalized, Person-Centered Health Assessments in Plastic Surgery. Journal of Medical Internet Research. 2023;25(1):e41870.
  2. Gallo L, Kim P, Yuan M, Gallo M, Thoma A, Voineskos SH, et al. Best Practices for FACE-Q Aesthetics Research: A Systematic Review of Study Methodology. Aesthetic surgery journal. 2023;43(9):NP674-NP86.
  3. Sierakowski KL, Dean NR, Evans Sanchez K, Griffin PA, Wormald JCR, Rodrigues JN, et al. The HAND-Q: Psychometrics of a New Patient-reported Outcome Measure for Clinical and Research Applications. Plastic and Reconstructive Surgery Global Open. 2022;10(1):e3998.
  4. Sierakowski K, Kaur MN, Sanchez K, Bain G, Cano SJ, Griffin P, et al. Qualitative study informing the development and content validity of the HAND-Q: a modular patient-reported outcome measure for hand conditions. BMJ Open. 2022;12(4):e052780.
  5. de Vries CEE, Tsangaris E, Makarawung DJS, Mink van der Molen AB, van Veen RN, Hoogbergen MM, et al. Validation of the Dutch Version of the BODY-Q Measuring Appearance, Health-Related Quality of Life, and Experience of Healthcare in Patients Undergoing Bariatric and Body Contouring Surgery. Aesthetic surgery journal. 2022;43(5):569-79.
  6. Klassen AF, Rae C, Wong Riff KW, Bulstrode N, Denadai R, Goldstein J, et al. FACE-Q Craniofacial Module: Part 1 validation of CLEFT-Q scales for use in children and young adults with facial conditions. Journal of plastic, reconstructive & aesthetic surgery : JPRAS. 2021.
  7. Klassen AF, Rae C, Riff W, Denadai R, Murray DJ, Bracken S, et al. FACE-Q craniofacial module: Part 2 Psychometric properties of newly developed scales for children and young adults with facial conditions. Journal of plastic, reconstructive & aesthetic surgery : JPRAS. 2021.
  8. Klassen AF, Rae C, Bulstrode NW, Berenguer B, Cui C, Fisher DM, et al. An international study to develop the EAR-Q patient-reported outcome measure for children and young adults with ear conditions. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2021;74(9):2341-8.
  9. Klassen AF, Rae C, Bulstrode NW, Berenguer B, Cui C, Fisher DM, et al. An international study to develop the EAR-Q patient-reported outcome measure for children and young adults with ear conditions. Journal of plastic, reconstructive & aesthetic surgery : JPRAS. 2021.
  10. Apon I, van Leeuwen N, Allori AC, et al. Rasch Analysis of Patient- and Parent-Reported Outcome Measures in the International Consortium for Health Outcomes Measurement Standard Set for Cleft Lip and Palate. Value Health. 2021;24(3):404-412.
  11. Voineskos SH, Klassen AF, Cano SJ, Pusic AL, Gibbons CJ. Giving Meaning to Differences in BREAST-Q Scores: Minimal Important Difference for Breast Reconstruction Patients. Plast Reconstr Surg. 2020;145(1):11e-20e.
  12. Poulsen L, Simonsen N, Klassen AF, Cano SJ, et al. Comparison of the Moorehead-Ardelt quality of life questionnaire and the BODY-Q in Danish patients undergoing weight loss and body contouring surgery. Clin Obes. 2020;10(2):e12351.
  13. Poulsen L, Lorenzen M, Simonsen N, Klassen A, Rose M, Juhl CB, et al. Patient-reported outcomes in weight loss and body contouring surgery: the voice of 1831 patients using the BODY-Q. ISOQOL; 2019; San Diego, CA, USA.
  14. Kaur M, Pusic A, Cano S, Bordeleau L, Tsangaris E, Klassen A. Examining content validity of BREAST-Q a decade later to determine relevance and comprehensiveness. ISOQOL; San Diego, CA, USA, 2019.
  15. Harrison CJ, Rae C, Tsangaris E, et al. Further construct validation of the CLEFT-Q: Ability to detect differences in outcome for four cleft-specific surgeries. Journal of plastic, reconstructive & aesthetic surgery : JPRAS. 2019;72(12):2049-2055.
  16. Klassen AF, Wong-Riff KWY, Longmire NM, Albert A, Allen GC, Aydiny MA, et al. Psychometric Findings and Normative Values for the CLEFT-Q based on 2,434 Children and Young Adult Patients with Cleft Lip and/or Palate from 12 Countries. Canadian Medical Association Journal. 2018;190(15):E455-62.
  17. Klassen AF, Kaur M, Breitkopf T, Thoma A, Cano S, Pusic A. Using the BODY-Q to Understand Impact of Weight Loss, Excess Skin and the Need for Body Contouring Following Bariatric Surgery. Plast Reconstr Surg. 2018.
  18. Browne JP, Jeevan R, Pusic AL, Klassen AF, Gulliver-Clarke C, Pereira J, et al. Measuring the patient perspective on latissimus dorsi donor site outcomes following breast reconstruction. Journal of plastic, reconstructive & aesthetic surgery : JPRAS. 2018;71(3):336-43.
  19. Wong Riff KW, Tsangaris E, Goodacre T, Forrest CR, Pusic AL, Cano SJ, et al. International multiphase mixed methods study protocol to develop a cross-cultural patient-reported outcome instrument for children and young adults with cleft lip and/or palate (CLEFT-Q). BMJ Open. 2017;7(1):e015467.
  20. Poulsen L, Klassen A, Rose M, Roessler KK, Juhl CB, Støving RK, et al. Psychometric validation of the BODY-Q in Danish patients undergoing weight loss and body contouring surgery. Plast Reconstr Surg Glob Open. 2017;5(10):e1529.
  21. Klassen AF, Cano SJ, Grotting JC, Baker SB, Carruthers J, Carruthers A, et al. FACE-Q Eye Module for Measuring Patient-Reported Outcomes Following Cosmetic Eye Treatments. JAMA Facial Plast Surg. 2017;19(1):7-14.
  22. Fuzesi S, Cano SJ, Klassen AF, Atisha D, Pusic AL. Validation of the electronic version of the BREAST-Q in the army of women study. Breast. 2017;33:44-9.
  23. Mundy LR, Miller HC, Klassen AF, Cano SJ, Pusic AL. Patient-Reported Outcome Instruments for Surgical and Traumatic Scars: A Systematic Review of their Development, Content, and Psychometric Validation. Aesthetic Plast Surg. 2016;40(5):792-800.
  24. Klassen AF, Cano SJ, Schwitzer JA, Baker SB, Carruthers A, Carruthers J, et al. Development and Psychometric Validation of the FACE-Q Skin, Lips, and Facial Rhytids Appearance Scales and Adverse Effects Checklists for Cosmetic Procedures. JAMA Dermatol. 2016;152(4):443-51.
  25. Klassen AF, Cano SJ, Pusic AL. Use of FACE-Q to Measure Quality of Life Following Aesthetic Facial Treatments. JAMA Facial Plast Surg. 2016;18(2):148-9.
  26. Klassen AF, Cano SJ, Pusic AL. FACE-Q Satisfaction with Appearance Scores from Close to 1000 Facial Aesthetic Patients. Plast Reconstr Surg. 2016;137(3):651e-2e.
  27. Klassen AF, Cano SJ, East CA, Baker SB, Badia L, Schwitzer JA, et al. Development and Psychometric Evaluation of the FACE-Q Scales for Patients Undergoing Rhinoplasty. JAMA Facial Plast Surg. 2016;18(1):27-35.
  28. Klassen AF, Cano SJ, Alderman A, Soldin M, Thoma A, Robson S, et al. The BODY-Q: A Patient-Reported Outcome Instrument for Weight Loss and Body Contouring Treatments. Plast Reconstr Surg Glob Open. 2016;4(4):e679.
  29. Klassen AF, Cano SJ, Alderman A, East C, Badia L, Baker SB, et al. Self-Report Scales to Measure Expectations and Appearance-Related Psychosocial Distress in Patients Seeking Cosmetic Treatments. Aesthet Surg J. 2016;36(9):1068-78.
  30. Klassen AF, Cano S, Pusic A. RHINO Scale: A Question about Content Validity. Plast Reconstr Surg Glob Open. 2016;4(8):e826.
  31. Cohen WA, Mundy LR, Ballard TN, Klassen A, Cano SJ, Browne J, et al. The BREAST-Q in surgical research: A review of the literature 2009-2015. Journal of plastic, reconstructive & aesthetic surgery : JPRAS. 2016;69(2):149-62.
  32. Cano S, Pendrill L. Metrological standards for use in healthcare decision making: An update on research involving the BREAST-Q. International Outcome Measurement Workshop; 2016; Washington, D.C., USA.
  33. Wong K, Tsangaris E, Goodacre T, Forrest C, Pusic A, Cano S, et al. CLEFT-Q - who’s ideal is it anyway. 72nd Annual Meeting & Pre-Conference Symposia of the American Cleft Palate-Craniofacial Association; 2015; Palm Springs, CA, USA.
  34. Wong K, Tsangaris E, Forrest C, Harman K, Pusic A, Cano S, et al. An early look: a mixed methods study to examine the feasibility, preliminary psychometric performance, and early construct validity of the CLEFT-Q. ISOQOL; Vancouver, Canada, 2015.
  35. Tsangaris E, Wong K, Forrest C, Pusic AL, Cano S, Goodacre T, et al. How qualitative methods can be used to ensure content validity in a PRO instrument for patients with cleft lip and/or palate who vary by age and culture: development of the CLEFT-Q. 72nd Annual Meeting & Pre-Conference Symposia of the American Cleft Palate-Craniofacial Association; 2015; Palm Springs, CA, USA.
  36. Tsangaris E, Wong K, Forrest C, Harman K, Pusic A, Cano S, et al. Determining the psychometric properties of the CLEFT-Q using two different sets of response options. ISOQOL; 2015; Vancouver, Canada.
  37. Schwitzer JA, Klassen AF, Cano SJ, Baker SB, East C, Pusic AL. Measuring Satisfaction with Appearance: Validation of the FACE-Q Scales for the Nose, Forehead, Cheekbones, and Chin. Plast Reconstr Surg. 2015;136(4 Suppl):140-1.
  38. Razdan SN, Scott AM, Cano S, Cordeiro PG, Pusic AL, McCarthy CM. Does the mind get what the mind expects? Patient expectations and satisfaction in breast reconstructive surgery: A pilot study. Plastic Surgery Research Council; 2015; Seattle, WA, USA.
  39. Klassen AF, Cano SJ, Schwitzer JA, Scott AM, Pusic AL. FACE-Q scales for health-related quality of life, early life impact, satisfaction with outcomes, and decision to have treatment: development and validation. Plast Reconstr Surg. 2015;135(2):375-86.
  40. Klassen A, Alderman A, Soldin M, Robson S, Kaur M, Cano S, et al. Development and psychometric validation of a PRO instrument for obese, bariatric and cosmetic body contouring patients: the BODY-Q. ISOQOL; 2015; Vancouver, Canada.
  41. Tsangaris E, Wong K, Forrest C, Pusic A, Cano S, Goodacre T, et al. How qualitative methods can be used to ensure content validity in a PRO instrument for patients with cleft lip and/or palate who vary by age and culture: development of the CLEFT-Q. ISOQOL; 2014; Berlin, Germany.
  42. Schwitzer J, Klassen AF, Cano SJ, Pusic AL. Towards Evidence-Based Practice in Cosmetic Surgery Using the Q-Portfolio of Patient-Reported Outcome Measures Aesthetic Journal. 2014;1(7):28-32.
  43. Pusic A, McCarthy C, Klassen A, Cano S, Cordeiro P. Health-related quality of life (HRQOL) following prophylactic mastectomy and reconstruction. ISOQOL; 2014; Berlin, Germany.
  44. Pusic A, Klassen A, Panchapakesan V, Cano S. Response to "The FACE-Q: the importance of full disclosure and sound methodology in outcomes studies". Aesthet Surg J. 2014;34(4):628-31.
  45. McCarthy CM, Mehrara BJ, Long T, Garcia P, Kropf N, Klassen AF, et al. Chest and upper body morbidity following immediate postmastectomy breast reconstruction. Annals of surgical oncology. 2014;21(1):107-12.
  46. Klassen AF, Cano SJ, Scott AM, Pusic AL. Measuring outcomes that matter to face-lift patients: development and validation of FACE-Q appearance appraisal scales and adverse effects checklist for the lower face and neck. Plast Reconstr Surg. 2014;133(1):21-30.
  47. Klassen AF, Cano SJ, Scott A, Tsangaris E, Pusic AL. Assessing outcomes in body contouring. Clinics in plastic surgery. 2014;41(4):645-54.
  48. Cano SJ, Klassen AF, Scott A, Alderman A, Pusic AL. Interpreting clinical differences in BREAST-Q scores: minimal important difference. Plast Reconstr Surg. 2014;134(1):173e-5e.
  49. Cano S. Outcome measurement in Rhinoplasty: The Prominence & Potential of Patient Reported Outcomes. Autumn Meeting of the British Society of Rhinoplasty Surgeons; 2014; Leicester, UK
  50. Cano S. Facial Assessment Scales in Clinical Practice: The Prominence & Potential of Patient Reported Outcomes. Facial Aesthetic Conference and Exhibition; 2014; London, UK
  51. Albornoz CR, Matros E, McCarthy CM, Klassen A, Cano SJ, Alderman AK, et al. Implant breast reconstruction and radiation: a multicenter analysis of long-term health-related quality of life and satisfaction. Annals of surgical oncology. 2014;21(7):2159-64.
  52. Wong KWY, Fayed N, Forrest CR, Goodacre T, Pusic A, Gosain A Klaus de Camargo O, et al. Content comparison of the qualitative data informing the CLEFT-Q to generic instruments (PedsQL 4.0, CHQ, KINDL) using the ICF-CY classification. 12th International Congress on Cleft Lip/Palate and Related Craniofacial Anomalies; 2013; Orlando, FL, USA.
  53. Wong K, Goodacre T, Forrest C, Pusic A, Cano S, Klassen A. CLEFT-Q: Cross-cultural and age-related similarities in developing a patient-reported outcome instrument for children with cleft lip and/or palate. ISOQOL; Miami, FL, USA, 2013.
  54. Wildgoose P, Scott A, Pusic AL, Cano S, Klassen AF. Psychological screening measures for cosmetic plastic surgery patients: a systematic review. Aesthet Surg J. 2013;33(1):152-9.
  55. Pusic AL, Klassen AF, Scott AM, Cano SJ. Development and psychometric evaluation of the FACE-Q satisfaction with appearance scale: a new patient-reported outcome instrument for facial aesthetics patients. Clinics in plastic surgery. 2013;40(2):249-60.
  56. Pusic A, Klassen AF, Scott AM, Cano S. Psychometric development of a new PRO instrument: The FACE-Q scales for facelift patients. Canadian Society of Plastic Surgery Meeting; 2013; Calgary, Canada.
  57. Panchapakesan V, Klassen AF, Cano SJ, Scott AM, Pusic AL. Development and psychometric evaluation of the FACE-Q Aging Appraisal Scale and Patient-Perceived Age Visual Analog Scale. Aesthet Surg J. 2013;33(8):1099-109.
  58. Klassen AF, Cano S, Scott AM, Pusic AL. Measuring Outcomes that Matter to Facelift Patients: The FACE-Q Appearance and Age Appraisal Scales and Adverse Effects Checklist. British Association of Aesthetic Plastic Surgeons; 2013; London, UK.
  59. Klassen A, Cano S, Scott AM, Pusic AL. Introducing FACE-Q Scales for Patient Screening and for Psychosocial Well-being. British Association of Aesthetic Plastic Surgeons; 2013; London, UK.
  60. Ho AL, Klassen AF, Cano S, Scott AM, Pusic AL. Optimizing patient-centered care in breast reconstruction: the importance of preoperative information and patient-physician communication. Plast Reconstr Surg. 2013;132(2):212e-20e.
  61. Cano SJ, Klassen AF, Scott AM, Pusic AL. A closer look at the BREAST-Q((c)). Clinics in plastic surgery. 2013;40(2):287-96.
  62. Cano SJ, Klassen AF, Scott A, Cordeiro PG, Pusic AL. Reply: The Rasch model: "Litmus Test" de rigueur for rating scales? Plast Reconstr Surg. 2013;131(2):286e-8e.
  63. Wong KWY, Fayed N, Forrest CR, Goodacre T, Pusic A, Gosain A, et al. Content comparison of the qualitative data informing the CLEFT-Q to generic instruments (Peds-QL 4.0, CHQ, KINDL) using the ICF-CY classification. ISOQOL; 2012; Budapest, Hungary.
  64. Wong KW, Goodacre T, Forrest CR, Pusic AL, Johnson J, Lawson J, et al. Informing the CLEFT-Q: Defining the gap in the measurement of health concepts important to patients with cleft lip and/or palate. Appearance Matters 5 2012; Bristol, UK.
  65. Wong KW, Goodacre T, Forrest CF, Pusic A, Gosain A, Johnson J, et al. Developing a Patient-Reported Outcome Measure for Cleft Lip and Palate (CLEFT-Q): Item Generation. Canadian Society of Plastic Surgeons Annual Meeting; 2012; Toronto, Canada.
  66. Scott AM, Cano S, Warren R, VanLaeken NY, Pusic AL. Measuring Quality of Life in Facial Aesthetic Patients: Field-testing of a new Modular system (THE FACE-Q). Canadian Society of Plastic Surgeons Annual Meeting; 2012; Toronto, Canada.
  67. Pusic AL, Klassen AF, Snell L, Cano SJ, McCarthy C, Scott A, et al. Measuring and managing patient expectations for breast reconstruction: impact on quality of life and patient satisfaction. Expert Rev Pharmacoecon Outcomes Res. 2012;12(2):149-58.
  68. Pusic AL, Klassen AF, Cano SJ. Discussion: The BREAST-Q: further validation in independent clinical trials. Plast Reconstr Surg. 2012;130(3):482e-3e; author reply 3e.
  69. Pusic AL, Klassen AF, Cano SJ. Use of the BREAST-Q in clinical outcomes research. Plast Reconstr Surg. 2012;129(1):166e-7e; author reply 7e.
  70. Pusic AL, Klassen A, Scott AM, Cano S. Measuring quality of life in facial aesthetic patients: Field testing of a new modular system (The FACE-Q). Appearance Matters 5; 2012; Bristol, UK.
  71. Pusic A, Klassen A, Scott AM, Cano S, Shouery M, Basch EM. Feasibility and acceptability of patient-reported outcomes data collection for clinical care following breast reconstruction. American Society of Clinical Oncology; 2012; Chicago, IL, USA.
  72. Pusic A, Cano S, Klassen A, Scott AM, Shouery M, Basch E, et al. Feasibility and acceptability of patient-reported outcomes data collection for clinical care following breast reconstruction. ISOQOL; Budapest, Hungary, 2012.
  73. Price AN, Scott AM, Klassen A, Cano S, Mehrara BJ, Disa JJ, et al. Patient-reported satisfaction with psychosocial and sexual well-being and the nipple areola complex: comparison of preservation and reconstruction. ISOQOL; Budapest, Hungary, 2012.
  74. Price AN, Pusic AL, Cano S, VanLaeken N, Johnson J, Klassen AF. The BODY-Q: A new patient-reported outcome (PRO) measure for body contouring patients. Canadian Society of Plastic Surgeons Annual Meeting; 2012; Toronto, Canada.
  75. McCarthy CM, Cano SJ, Klassen AF, Scott A, Van Laeken N, Lennox PA, et al. The magnitude of effect of cosmetic breast augmentation on patient satisfaction and health-related quality of life. Plast Reconstr Surg. 2012;130(1):218-23.
  76. Klassen AF, Tsangaris E, Forrest CR, Wong KW, Pusic AL, Cano SJ, et al. Quality of life of children treated for cleft lip and/or palate: a systematic review. Journal of plastic, reconstructive & aesthetic surgery : JPRAS. 2012;65(5):547-57.
  77. Klassen AF, Cano SJ, Scott A, Johnson J, Pusic AL. Satisfaction and quality-of-life issues in body contouring surgery patients: a qualitative study. Obesity surgery. 2012;22(10):1527-34.
  78. Ho AL, Klassen A, Cano S, Scott AM, Pusic A. Optimizing satisfaction in breast reconstruction: the importance of the preoperative information and patient-physician communication. ISOQOL; Budapest, Hungary, 2012.
  79. Cano SJ, Klassen AF, Scott AM, Cordeiro PG, Pusic AL. The BREAST-Q: further validation in independent clinical samples. Plast Reconstr Surg. 2012;129(2):293-302.
  80. Albornoz CR, Matros M, Pusic A, Klassen A, Cano S, McCarthy C, et al. Breast reconstruction and radiation: an analysis of quality of life and satisfaction among patients undergoing implant reconstruction. ISOQOL; 2012; Budapest, Hungary.
  81. Scott AM, Klassen AF, Pusic AL, Cano S, Cordeiro PG, Morrow M, et al. Adaptation of existing PRO measures for use in additional patient populations: The BREAST-Q© BCT Module. ISOQOL; 2011; Denver, CO, USA.
  82. Scott A, Pusic AL, Cano SJ, Johnson J, Lawson JL, Wildgoose P, et al. The BODY-Q: A New Patient-Reported Outcome (PRO) Measure for Body Contouring Patients (CP). ISOQOL; Denver, CO, USA 2011.
  83. Reavey PL, Klassen AF, Cano SJ, McCarthy C, Scott A, Rubin JP, et al. Measuring quality of life and patient satisfaction after body contouring: a systematic review of patient-reported outcome measures. Aesthet Surg J. 2011;31(7):807-13.
  84. Pusic AL, Lemaine V, Klassen AF, Scott AM, Cano SJ. Patient-reported outcome measures in plastic surgery: use and interpretation in evidence-based medicine. Plast Reconstr Surg. 2011;127(3):1361-7.
  85. Klassen A, Goodacre T, Wong K, Pusic A, Cano S, Tsangaris E, et al. Developing a Patient-Reported Outcome Measure for Cleft-Lip and/or Palate Patients. ISOQOL; 2011; Denver, CO, USA.
  86. Chen CM, Klassen AF, Cano SJ, Pusic AL. BCTOS in Measuring HR-QoL After Breast-Conserving Therapy. The Breast Journal. 2011;17(4):443.
  87. Cano SJ, Pusic AL, Klassen A. From BREAST-Q © to Q-Score ©: Using Rasch Measurement to better capture breast surgery outcomes. Proceedings from the Joint International IMEKO TC1+ TC7+ TC13 Symposium. 2011:82-94.
  88. Snell LJ, Cano SJ, Klassen AF, McCarthy CM, Scott AM, Cordeiro PG, et al. Measuring and managing patient expectation for breast reconstruction: A new preoperative patient assessment tool. ISOQOL; 2010; London, UK.
  89. Snell L, McCarthy C, Klassen A, Cano S, Rubin L, Hurley K, et al. Clarifying the expectations of patients undergoing implant breast reconstruction: a qualitative study. Plast Reconstr Surg. 2010;126(6):1825-30.
  90. Scott AM, McCarthy CM, Klassen AF, Cano SJ, Pusic AL, Jhanwar SM. Development of a new BREAST-Q module for Breast Cancer Patients: The Breast-Conserving Therapy (BCT) Module ISOQOL; London, UK, 2010.
  91. Pusic AL, Klassen AF, Scott AM, Cano SJ. Discussion. The measure of face-lift patient satisfaction: the Owsley Facelift Satisfaction Survey with a long-term follow-up study. Plast Reconstr Surg. 2010;126(1):258-60.
  92. McCarthy CM, Klassen AF, Cano SJ, Scott A, Vanlaeken N, Lennox PA, et al. Patient satisfaction with postmastectomy breast reconstruction: a comparison of saline and silicone implants. Cancer. 2010;116(24):5584-91.
  93. Klassen AF, Cano SJ, Scott A, Snell L, Pusic AL. Measuring patient-reported outcomes in facial aesthetic patients: development of the FACE-Q. Facial plastic surgery : FPS. 2010;26(4):303-9.
  94. Chen CM, Cano SJ, Klassen AF, King T, McCarthy C, Cordeiro PG, et al. Measuring quality of life in oncologic breast surgery: a systematic review of patient-reported outcome measures. The breast journal. 2010;16(6):587-97.
  95. Rubin LR, Klassen A, Cano SJ, Hurley K, Pusic AL. Motivations for breast surgery: a qualitative comparison study of breast reconstruction, augmentation, and reduction patients. The breast journal. 2009;15(6):666-7.
  96. Pusic AL, Reavey PL, Klassen AF, Scott A, McCarthy C, Cano SJ. Measuring patient outcomes in breast augmentation: introducing the BREAST-Q Augmentation module. Clinics in plastic surgery. 2009;36(1):23-32, v.
  97. Pusic AL, Klassen AF, Scott AM, Klok JA, Cordeiro PG, Cano SJ. Development of a new patient-reported outcome measure for breast surgery: the BREAST-Q. Plast Reconstr Surg. 2009;124(2):345-53.
  98. Kosowski TR, McCarthy C, Reavey PL, Scott AM, Wilkins EG, Cano SJ, et al. A systematic review of patient-reported outcome measures after facial cosmetic surgery and/or nonsurgical facial rejuvenation. Plast Reconstr Surg. 2009;123(6):1819-27.
  99. Klassen AF, Pusic AL, Scott A, Klok J, Cano SJ. Satisfaction and quality of life in women who undergo breast surgery: a qualitative study. BMC women's health. 2009;9:11-18.
  100. Cano SJ, Klassen A, Pusic AL. The science behind quality-of-life measurement: a primer for plastic surgeons. Plast Reconstr Surg. 2009;123(3):98e-106e.
  101. Pusic AL, McCarthy C, Cano SJ, Klassen AF, Kerrigan CL. Clinical research in breast surgery: reduction and postmastectomy reconstruction. Clinics in plastic surgery. 2008;35(2):215-26.
  102. Pusic AL, Klassen A, Cano SJ, Kerrigan CL. Validation of the breast evaluation questionnaire. Plast Reconstr Surg. 2007;120(1):352-3.
  103. Pusic AL, Chen CM, Cano S, Klassen A, McCarthy C, Collins ED, et al. Measuring quality of life in cosmetic and reconstructive breast surgery: a systematic review of patient-reported outcomes instruments. Plast Reconstr Surg. 2007;120(4):823-37; discussion 38-9.
  104. Cano SJ, Browne JP, Lamping DL, Roberts AH, McGrouther DA, Black NA. The Patient Outcomes of Surgery-Head/Neck (POS-head/neck): a new patient-based outcome measure. Journal of plastic, reconstructive & aesthetic surgery : JPRAS. 2006;59(1):65-73.
  105. Cano SJ, Browne JP, Lamping DL. Patient-based measures of outcome in plastic surgery: current approaches and future directions. British journal of plastic surgery. 2004;57(1):1-11.
  1. Arbuckle R, Halstead P, Marshall C, et al. Testing and Psychometric Validation of a Pediatric Instrument to Self-Assess Symptoms of the Common Cold. Patient. 2020.
  2. Loubert A, Regnault A, Meunier J, Gutzwiller FS, Regnier SA. Is the St. George’s Respiratory Questionnaire an Appropriate Measure of Symptom Severity and Activity Limitations for Clinical Trials in COPD? Analysis of Pooled Data from Five Randomized Clinical Trials. Int J Chron Obstruct Pulmon Dis. 2020;15:2103-2113.
  3. Winck JC, Gilet H, Kalin P, Murcia J, Plano F, Regnault A, et al. Validation of the Multi-INdependence Dimensions (MIND) questionnaire for prolonged mechanically ventilated subjects. BMC pulmonary medicine. 2019;19(1):109.
  4. Lapillonne A, Regnault A, Gournay V, Gouyon JB, Benmedjahed K, Anghelescu D, et al. Development of a questionnaire to assess the impact on parents of their infant's bronchiolitis hospitalization. BMC Health Serv Res. 2013;13(1):272.
  5. Regnault A, Balp MM, Kulich K, Viala-Danten M. Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis. J Cyst Fibros. 2012;11(6):494-501.
  6. Lapillonne A, Regnault A, Gournay V, Gouyon JB, Gilet H, Anghelescu D, et al. Impact on parents of bronchiolitis hospitalization of full-term, preterm and congenital heart disease infants. BMC Pediatr. 2012;12:171.
  7. Regnault A, Balp MM, Kulich K, Estève L, Viala-Danten M. Association of treatment satisfaction and compliance of cystic fibrosis (CF) patients using inhaled tobramycin treatment in the EAGER study. 34th European Cystic Fibrosis Conference; Hamburg, Germany, 2011.
  8. Regnault A, Balp MM, Kulich K, Estève L, Viala-Danten M. Validation of the treatment satisfaction questionnaire for medication (TSQM) in cystic fibrosis (CF). 34th European Cystic Fibrosis Conference; 2011; Hamburg, Germany.
  9. Gonzalez-Bermejo J, Aguilaniu B, Mueser M, Regnault A, Similowski T. Etude ADL- Typologie des patients. 15e congrès de Pneumologie de Langue Française; 2011; Lille, France.
  10. Aguilaniu B, Gonzalez-Bermejo J, Regnault A, Dias-Barbosa C, Arnould B, Mueser M, et al. Disability related to COPD tool (DIRECT): towards an assessment of COPD-related disability in routine practice. Int J Chron Obstruct Pulmon Dis. 2011;6:387-98.
  11. Gonzalez-Bermejo J, Aguilaniu B, Mueser M, Regnault A, Arnould B, Dias-Barbosa C, et al. Etude ADL. Validation du questionnaire BPCO et Activités quotidiennes, un questionnaire court d'évaluation du handicap des patients BPCO. 14ème congrès de Pneumologie de Langue Française; 2010; Marseille, France.
  12. Regnault A, Mueser M, Dias-Barbosa C, Aguilaniu B, Bonnefoy M, Gonzalez-Bermejo J, et al. Item selection and scoring definition of a disease-specific instrument to assess the handicap in chronic obstructive pulmonary disease (COPD) patients, for use in clinical routine practice. ISPOR; Paris, France, 2009.
  13. Lamping DL, Schroter S, Marquis P, Marrel A, Duprat-Lomon I, Sagnier PP. The community-acquired pneumonia symptom questionnaire: a new, patient-based outcome measure to evaluate symptoms in patients with community-acquired pneumonia. Chest. 2002;122(3):920-9.
  14. Marquis P, Trudeau E. Quality of life and patient satisfaction: two important aspects in asthma therapy. Curr Opin Pulm Med. 2001;7 Suppl 1:S18-20.
  15. Bousquet J, Duchateau J, Pignat JC, Fayol C, Marquis P, Mariz S, et al. Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire. J Allergy Clin Immunol. 1996;98(2):309-16.
  16. Bousquet J, Bullinger M, Fayol C, Marquis P, Valentin B, Burtin B. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol. 1994;94(2 Pt 1):182-8.
  1. Rams A, Baldasaro J, Bunod L, Delbecque L, Strzok S, Meunier J, et al. Assessing Itch Severity: Content Validity and Psychometric Properties of a Patient-Reported Pruritus Numeric Rating Scale in Atopic Dermatitis. Adv Ther. 2024;41(4):1512-25.
  2. Rams A, Baldasaro J, Bunod L, Delbecque L, Strzok S, Meunier J, et al. Sleep-loss related to itch in atopic dermatitis: assessing content validity and psychometric properties of a patient-reported sleep-loss rating scale. Journal of Patient-Reported Outcomes. 2024;8:77.
  3. Yosipovitch G, Rams A, Baldasaro J, Bunod L, Delbecque L, Strzok S, et al. CONTENT VALIDITY AND ASSESSMENT OF THE PSYCHOMETRIC PROPERTIES AND SCORE INTERPRETATION OF A PRURITUS NUMERIC RATING SCALE IN ATOPIC : DERMATITIS. Revolutioninzing Atopic Dermatitis (RAD); Baltimore, MD2021.
  4. Yosipovitch G, Rams A, Baldasaro J, Bunod L, Delbecque L, Strzok S, et al. CONTENT VALIDITY AND ASSESSMENT OF THE PSYCHOMETRIC PROPERTIES AND SCORE INTERPRETATION OF A SLEEP-LOSS SCALE SCORE IN ATOPIC DERMATITIS. Revolutionizing Atopic Dermatitis; Baltimore, MD2021.
  5. Lee EH, Pusic AL, Cano SJ, Klassen AF. The FACE-Q Skin Cancer Module addresses post-resection aesthetic and quality of life outcomes. British Journal of Dermatology. 2019;180(4):953-4.
  6. Klassen AF, Lipner S, O'Malley M, Longmire NM, Cano SJ, Breitkopf T, et al. Development of a New Patient-Reported Outcome Measure to Evaluate Treatments for Acne and Acne Scarring: The ACNE-Q. The British journal of dermatology. 2019.
  7. Lee EH, Pusic AL, Cano SJ, Klassen AF. The FACE-Q Skin Cancer Module addresses post-resection aesthetic and quality of life outcomes. The British journal of dermatology. 2018.
  8. Lee EH, Klassen AF, Cano SJ, Nehal KS, Pusic AL. FACE-Q Skin Cancer Module for Measuring Patient-Reported Outcomes Following Facial Skin Cancer Surgery. The British journal of dermatology. 2018.
  9. Lee EH, Klassen AF, Lawson JL, Cano SJ, Scott AM, Pusic AL. Patient experiences and outcomes following facial skin cancer surgery: A qualitative study. Australas J Dermatol. 2016;57(3):e100-4.
  10. Rutherford C, Nixon J, Brown JM, Lamping DL, Cano SJ. Using mixed methods to select optimal mode of administration for a patient-reported outcome instrument for people with pressure ulcers. BMC medical research methodology. 2014;14:22.
  11. Lee E, Klassen A, Cano S, Lawson J, Scott A, Pusic A. Hearing the Patient’s Voice: Quality of life Outcomes in Dermatologic Surgery. American College of Mohs Surgery; 2014; Phoenix, AZ, USA.
  12. Lee EH, Klassen AF, Nehal KS, Cano SJ, Waters J, Pusic AL. A systematic review of patient-reported outcome instruments of nonmelanoma skin cancer in the dermatologic population. Journal of the American Academy of Dermatology. 2013;69(2):e59-67.
  13. Lee EH, Klassen A, Lawson JL, Cano SJ, Scott AM, Nehal KS, et al. A qualitative study to develop a conceptual framework to understand the health concerns of patients who undergo facial surgery for skin cancer. ISOQOL; Miami, FL, USA, 2013.
  14. Gorecki C, Brown JM, Cano S, Lamping DL, Briggs M, Coleman S, et al. Development and validation of a new patient-reported outcome measure for patients with pressure ulcers: the PU-QOL instrument. Health Qual Life Outcomes. 2013;11:95.
  15. Gorecki C, Lamping DL, Nixon J, Brown JM, Cano S. Applying mixed methods to pretest the Pressure Ulcer Quality of Life (PU-QOL) instrument. Qual Life Res. 2012;21(3):441-51.
  16. Cano SJ, Browne JP, Lamping DL, Roberts AH, McGrouther DA, Black NA. The Patient Outcomes of Surgery-Head/Neck (POS-head/neck): a new patient-based outcome measure. Journal of plastic, reconstructive & aesthetic surgery : JPRAS. 2006;59(1):65-73.
  1. Marrel A, Lanar S, Markowitz JT, Acebo C, Black J, Vanhove GF, et al. The Paediatric Narcolepsy Screening Questionnaire – data from the evaluation of a new tool to help paediatricians identify narcolepsy. Annual Meeting of the European Sleep Research Society; Bologna, Italy, 2016.
  2. Marquis P. Sleep disturbance. A component of health status. Pharmacoeconomics. 1996;10 Suppl 1:25-8.
  1. Acquadro C, Perret C, Regnault A. Pro Claims in Fibromyalgia: A Review of the Labels of Products Approved by the FDA and the EMA. ISPOR; Milan, Italy, 2015.
  2. Baron R, Backonja MM, Eldridge P, Levy R, Vissers K, Attal N, et al. Refractory Chronic Pain Screening Tool (RCPST): a feasibility study to assess practicality and validity of identifying potential neurostimulation candidates. Pain Med. 2014;15(2):281-91.
  3. Gilet H, Arnould B, Regnault A. Applying partial least squares discriminant analysis (PLS-DA) for optimisation of decision rules based on complex patient-reported data: creation of the FibroDetect® scoring method. International Society for Clinical Biostatistics (ISCB) 33rd Annual Conference; Bergen, Norway, 2012.
  4. Cano SJ, Hobart JC. Validity in fatigue measurement: complementing quality and quantity. ISOQOL; 2010; London, UK
  5. Branski RC, Cukier-Blaj S, Pusic A, Cano SJ, Klassen A, Mener D, et al. Measuring quality of life in dysphonic patients: a systematic review of content development in patient-reported outcomes measures. Journal of voice : official journal of the Voice Foundation. 2010;24(2):193-8.
  6. Evans CJ, Trudeau E, Mertzanis P, Marquis P, Pena BM, Wong J, et al. Development and validation of the Pain Treatment Satisfaction Scale (PTSS): a patient satisfaction questionnaire for use in patients with chronic or acute pain. Pain. 2004;112(3):254-66.
  1. Martinez L, Arnould P, Duhot D, Coindard G, Seyler D, Fofana F, Meunier J, et al. Les éléments explicatifs de l'engagement des MG vis-à-vis de la vaccination: Apports de l'étude DIVA. 9ème Congrès de Médecine Générale; 2015; Paris, France.
  2. Arnould B, Fofana F, Meunier J, Coindard G, Seyler D, Duhot D, et al. DIVA (Déterminants des Intentions de Vaccination): Validation psychométrique du questionnaire. 9ème Congrès de Médecine Générale; 2015; Paris, France.
  3. Reygrobellet C, Viala-Danten M, Meunier J, Weber F, Nguyen VH. Perception and acceptance of intradermal influenza vaccination: Patient reported outcomes from phase 3 clinical trials. Hum Vaccin. 2010;6(4):336-45.
  1. Bakri SJ, Amoaku WMK, Altman D, Quéré S, Quilantan J, Carpenter-Conlin J, et al. The MOSAIC Study: A Mixed-Methods Study of the Clinical, Emotional, and Financial Burden of Geographic Atrophy Among Patients and Caregivers in the US. OPTH. 2024;18:2357-68.
  2. Sherman SA, Rofail D, Levine A, Hartford CR, Baldasaro J, Marquis P, et al. The Patient Experience with Diabetic Retinopathy: Qualitative Analysis of Patients with Proliferative Diabetic Retinopathy. Ophthalmol Ther. 2023;12(1):431-46.
  3. Rofail D, Sherman S, Hartford C, Levine A, Baldasaro J, Marquis P, et al. Development and Preliminary Validation of an Instrument to Measure Symptoms and Impacts in Patients with Proliferative Diabetic Retinopathy. Adv Ther. 2023;40(4):1773-86.
  4. Quilantan J, Réaume C, Amoaku W, Quéré S, M’Hari M, Carpenter-Conlin J, et al. The MOSAIC Study: A clinical and humanistic burden of illness study among patients with geographic atrophy (GA) and their caregivers in the United States (US) and Canada (CA). Investigative Ophthalmology & Visual Science. 2023;64(8):3722.
  5. Boboridis KG, Messmer E, Benítez-del-Castillo J, Meunier J, Sloesen B, O’Brien P, et al. Patient-reported burden and overall impact of dry eye disease across eight European countries: a cross-sectional web-based survey. BMJ Open. 2023;13(3):e067007.
  6. Jones D, Nielsen J, Altman D, Carpenter-Conlin J, Lui B, Marquis P, et al. MOSAIC: A qualitative study of the clinical, humanistic, and financial burden of geographic atrophy (GA) among patients. Investigative Ophthalmology & Visual Science. 2022;63(7):4217-A0145.
  7. Amoaku W, Altman D, Sarda SP, Lui B, Carpenter-Conlin J, Marquis P, et al. PCR144 Mosaic: A Qualitative Study of the Humanistic and Financial Burden on Unpaid Caregivers of Patients with Geographic Atrophy (GA). Value in Health. 2022;25(7):S568.
  8. Hossain P, Siffel C, Joseph C, Meunier J, Markowitz JT, Dana R. Patient-reported burden of dry eye disease in the UK: a cross-sectional web-based survey. BMJ Open. 2021;11(3):e039209.
  9. Sloesen B, Meunier J, Markowitz JT, et al. Patient-Reported Burden of Dry Eye Disease in Germany: Results of an Online Cross-Sectional Survey. ISPOR; 2020.
  10. Dana R, Meunier J, Markowitz JT, Joseph C, Siffel C. Patient-Reported Burden of Dry Eye Disease in the United States: Results of an Online Cross-Sectional Survey. Am J Ophthalmol. 2020; 216:7-17.
  11. Skelly A, Loubert A, Goswami P, Meunier J, Regnault A. Confirmation of the measurement properties of the National Eye Institute Visual Functioning Questionnaire 28 Item Rasch-based scoring in neovascular Age-related Macular Degeneration. ISPOR; 2019; Copenhagen, Denmark.
  12. Siffel C, Markowitz JT, Meunier J, Sarda SP, Joseph C. Dry Eye Disease has a Negative Impact on Health Status - NEI-VFQ-25 Based Utility Assessment from an Online Survey in the US and UK. ISPOR; New Orleans, LA, USA, 2019.
  13. Stillman I, Markowitz JT, Meunier J, Marquis P, Joseph C, Siffel C, et al. Eye Dryness Score Is a Useful Single-Item Indicator of Dry Eye Severity: Data From a US Patient Survey. American Academy of Ophthalmology Annual meeting; Chicago, IL, USA, 2018.
  14. Stillman I, Markowitz JT, Marquis P, Meunier J, Siffel C, Joseph C, et al. Negative Impact of Dry Eye Disease on Health- and Vision-Related Quality of Life: Results of an Online Survey in the United States. American Academy of Ophthalmology Annual meeting; Chicago, IL, USA, 2018.
  15. Stillman I, Hossain P, Markowitz JT, Meunier J, Joseph C, Siffel C, et al. Eye Dryness Score is a Useful Single-Item Tool to Assess Severity of Dry Eye Symptoms: Data From a United Kingdom (UK) Patient Survey European Society of Cataract and Refractive Surgeons Congress; 2018; Vienna, Austria.
  16. Hossain P, Markowitz JT, Marquis P, Meunier J, Joseph C, Siffel C, et al. Impact of dry eye disease increases with severity of symptoms: results from a patient survey in the UK. European Society of Cataract and Refractive Surgeons Congress; Vienna, Austria, 2018.
  17. Hossain P, Markowitz JT, Marquis P, Meunier J, Joseph C, Siffel C, et al. Negative impact of dry eye disease on health status and vision-related quality of life. European Society of Cataract and Refractive Surgeons Congress; Vienna, Austria, 2018.
  18. Dana R, Stillman I, Cleanthous S, Markowitz JT, Marquis P. Patient-reported outcomes measurements in Dry Eye Disease: conceptual framework and assessment of existing instruments. World Ophthalmology Congress; 2018; Barcelona, Spain.
  19. Petrillo J, Bressler NM, Lamoureux E, Ferreira A, Cano S. Development of a new Rasch-based scoring algorithm for the National Eye Institute Visual Functioning Questionnaire to improve its interpretability. Health Qual Life Outcomes. 2017;15(1):157.
  20. Souied EH, Oubraham H, Mimoun G, Cohen SY, Quere S, Derveloy A. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: The TWIN Study. Retina (Philadelphia, Pa). 2015;35(9):1743-9.
  21. Petrillo J, Ferreira A, Cano S, Bressler NM, Lamoureux E. Psychometric Performance Of The Nei Vfq-25: Rasch Analysis Of The Nei Vfq-25 As A Measure Of Patient-Reported Visual Function Across Four Retinal Diseases. ISPOR; New Orleans, LA, USA, 2013.
  22. Coon CD, Cano SJ, Petrillo J, Ferreira A, Bressler NM, Lee P, et al. Assessment of the relative precision of the NEI VFQ-25 and a modified, Rasch-scored NEI VFQ in clinical trial data for patients with diabetic macular edema (DME). ISOQOL; 2013; Miami, FL, USA.
  23. Cohen SY, Mimoun G, Oubraham H, Zourdani A, Malbrel C, Quere S, et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina (Philadelphia, Pa). 2013;33(3):474-81.
  24. Tugaut B, Meunier J, Viala-Danten M, Arnould B, Berdeaux G. Vision-related quality of life (QOL) after cataract refractive surgery. ISPOR; Prague, Czech Republic, 2010.
  25. Regnault A, Viala-Danten M, Gilet H, Berdeaux G. Scoring and psychometric properties of the Eye-Drop Satisfaction Questionnaire (EDSQ), an instrument to assess satisfaction and compliance with glaucoma treatment. BMC Ophthalmol. 2010;10:1.
  26. Nordmann JP, Baudouin C, Renard JP, Denis P, Regnault A, Berdeaux G. Identification of noncompliant glaucoma patients using Bayesian networks and the Eye-Drop Satisfaction Questionnaire. Clin Ophthalmol. 2010;4:1489-96.
  27. Cochener B, Fernandez-Vega L, Alfonso JF, Maurel F, Meunier J, Berdeaux G. Spectacle independence and subjective satisfaction of ReSTOR multifocal intraocular lens after cataract or presbyopia surgery in two European countries. Clin Ophthalmol. 2010;4:81-9.
  28. Berdeaux G, Meunier J, Arnould B, Viala-Danten M. Measuring benefits and patients' satisfaction when glasses are not needed after cataract and presbyopia surgery: scoring and psychometric validation of the Freedom from Glasses Value Scale (FGVS). BMC Ophthalmol. 2010;10:15.
  29. Regnault A, Viala-Danten M, Vigneux M, Berdeaux G. Identifying non compliant glaucoma patients using the EDSQ, a questionnaire measuring satisfaction and compliance of glaucoma treatment. ISPOR; Athens, Greece, 2008.
  30. Regnault A, Viala-Danten M, Vigneux M, Berdeaux G. Scoring and Psychometric Properties of the Eye-Drop Satisfaction Questionnaire (EDSQ). ISPOR; Athens, Greece, 2008.
  31. Meunier J, Berdeaux G, Arnould B, Viala-Danten M. Scoring and psychometric validation of the Freedom from Glasses Value Scale (FGVS). ISPOR; Athens, Greece, 2008.
  32. Berdeaux G, Feneron D, Meunier J, Viala-Danten M, Arnould B, Maurel F. Effectiveness of the ReSTOR multifocal intraocular lens in cataract and presbyopia surgery in two European countries. ISPOR; Athens, Greece, 2008.
  1. William PF, Stefan JC. Person-Centered Outcome Metrology: Principles and Applications for High Stakes Decision Making: Springer Cham; 2023 2023.
  2. Melin J, Cano SJ, Flöel A, Göschel L, Pendrill LR. Metrological advancements in cognitive measurement: A worked example with the NeuroMET memory metric providing more reliability and efficiency. Measurement: Sensors. 2023;25:100658.
  3. Melin J, Cano S, Göschel L, Flöel A, Pendrill L, This project has received funding from the Epc-fbtPS, et al. NeuroMET Memory Metric: Improving accuracy and comparability with crosswalks. Alzheimer's & Dementia. 2023;19(S4):e063924.
  4. Lawrance R, Skaltsa K, Regnault A, Floden L. Reflections on estimands for patient-reported outcomes in cancer clinical trials. Journal of Biopharmaceutical Statistics. 2023;0(0):1-11.
  5. Melin J, Cano S, Flöel A, Göschel L, Pendrill L. The Role of Entropy in Construct Specification Equations (CSE) to Improve the Validity of Memory Tests: Extension to Word Lists. Entropy. 2022;24(7):934.
  6. Loubert A, Regnault A, Sébille V, Hardouin J-B. Evaluating the impact of calibration of patient-reported outcomes measures on results from randomized clinical trials: a simulation study based on Rasch measurement theory. BMC medical research methodology. 2022;22(1):224.
  7. Salzberger T, Cano S, Abetz-Webb L, Afolalu E, Chrea C, Weitkunat R, et al. Addressing traceability of self-reported dependence measurement through the use of crosswalks. Measurement. 2021;181:109593.
  8. Quaglia M, Cano S, Fillmer A, Flöel A, Giangrande C, Göschel L, et al. The NeuroMET project: Metrology and innovation for early diagnosis and accurate stratification of patients with neurodegenerative diseases. 2021 Alzheimer's Association International Conference; 2021 2021; Virtual.
  9. Melin J, Cano SJ, Flöel A, Göschel L, Pendrill LR. Construct specification equations: ‘Recipes’ for certified reference materials in cognitive measurement. Measurement: Sensors. 2021;18:100290.
  10. Melin J, Cano S, Pendrill L. The Role of Entropy in Construct Specification Equations (CSE) to Improve the Validity of Memory Tests. Entropy (Basel). 2021;23(2).
  11. Melin J, Cano S, Flöel A, Göschel L, Pendrill L. More than a memory test: A new metric linking blocks, numbers, and words. 2021 Alzheimer's Association International Conference; 2021 2021; Virtual.
  12. Calvert M, King M, Mercieca-Bebber R, et al. SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials. BMJ Open. Jun 30 2021;11(6):e045105.
  13. Regnault A. A brief (non-exhaustive) overview of recent applications of mixed methods research in patient-centred outcome research. Paper presented at: ISOQOL (Industry SIG symposium)2020.
  14. Marquis S, Regnault A. Psychometric analyses of repeated measures using longitudinal extensions of the Rasch model and partial credit model with invariant frame of reference over time. Paper presented at: ISOQOL (oral presentation)2020.
  15. Loubert A, Regnault A, Sébille V, et al. Contemplating clinical trials as measurement systems: A new perspective for measurement uncertainty associated with treatment benefit demonstration. Paper presented at: ISOQOL (oral presentation)2020.
  16. Loubert A, Regnault A, Sébille V, Cano S, Hardouin JB. Should we calibrate PRO instruments in clinical trials? A comprehensive simulation study based on Rasch Measurement Theory. ISOQOL; 2020.
  17. Smith S, Cano S, Browne J. Patient reported outcome measurement: drawbacks of existing methods. BMJ (Clinical research ed). 2019;364:l844.
  18. Regnault A, Martin M, Eremenco S, McLeod L, Hudgens S. Clinical Outcome Assessment in a Multi Cultural Context: Measurement Challenges and Solutions (workshop). ISOQOL; 2019; San Diego, CA, USA.
  19. Pendrill L, Melin J, J Cano S, consortium tENH. Metrological references for health care based on entropy. International Congress of Metrology. 2019:07001.
  20. Melin J, Pendrill LR, Cano SJ. Towards patient-centred cognition metrics. IMEKO TC1-TC7-TC13-TC18 Joint Symposium 2019; St Petersburg, Russia.
  21. Loubert A, Regnault A, Sébile V, Cano S, Hardouin JB. Calibrating Rasch measures for assessing treatment effects in a clinical trial setting: Findings from a simulation study. ISOQOL; San Diego, CA, USA, 2019.
  22. Cleanthous S, Barbic SP, Smith S, Regnault A. Psychometric performance of the PROMIS(R) depression item bank: a comparison of the 28- and 51-item versions using Rasch measurement theory. J Patient Rep Outcomes. 2019;3(1):47.
  23. Cano SJ, Pendrill LR, Melin J, Fisher WP. Towards consensus measurement standards for patient-centered outcomes. Measurement. 2019;141:62-9.
  24. Browne JP, Cano SJ. A Rasch Measurement Theory Approach to Improve the Interpretation of Patient-reported Outcomes. Medical care. 2019;57 Suppl 5 Suppl 1:S18-s23.
  25. Regnault A, Cleanthous S, Markowitz JT, Marquis P, Cano SJ. A Mixed Methods Psychometrics Framework to Reduce the Uncertainty in the Measurement of Patient-Centered Outcomes. Institute of Objective Measurement Workshop; 2018; New York, NY, USA.
  26. Pendrill LR, Cano S, Köbe T, Melin J, Fillmer A. Restitution of ability and difficulty from decision-making: metrology of human-based perceptions. Measurement at the Crossroads: History, Philosophy, and Sociology of Measurement; 2018; Paris, France.
  27. Markowitz J, Regnault A, Cleanthous S, Marquis P, Cano S. Picking up the pace: the case for mixed methods research in pharmaceutical clinical trials. Society of Behavioral Medicine; New Orleans, LA, USA, 2018.
  28. Cano SJ, Pendrill LR, Melin J, Köbe T, Fisher WP, Stenner AJ. Metrology for the Social Sciences: A case for Rasch Measurement Theory (not Rasch Analysis). Institute of Objective Measurement Workshop; 2018; New York, NY, USA.
  29. Cano SJ, Pendrill LR, Barbic SP, Fisher WP. Patient-centred outcome metrology for healthcare decision-making. Journal of Physics: Conference Series. 2018;1044(1):012057.
  30. Cano SJ. Generalizability of validity data across diseases and treatment settings: when is enough, enough? ISOQOL; 2018; Dublin, Ireland.
  31. Cano S, Melin J, Fisher WP, Stenner AJ, Pendrill L, EMPIR-NeuroMet-15HLT04-consortium. Patient-centred cognition metrology. Journal of Physics: Conference Series. 2018;1065:072033.
  32. Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan AW, King MT, et al. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. Jama. 2018;319(5):483-94.
  33. Brundage M, Wu AW, Rivera Y, Cano S, Dueck A, Jensen R, et al. Methods for aiding interpretation of PRO scores. ISOQOL; 2018; Dublin, Ireland.
  34. Regnault A, Willgoss T, Barbic S. Towards the use of mixed methods inquiry as best practice in health outcomes research. Journal of Patient-Reported Outcomes. 2017;2(1):19.
  35. Powers JH, 3rd, Patrick DL, Walton MK, Marquis P, Cano S, Hobart J, et al. Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force. Value Health. 2017;20(1):2-14.
  36. Mcclimans L, Browne J, Cano S. Clinical outcome measurement: Models, theory, psychometrics and practice. Studies in History and Philosophy of Science. 2017;65-66:67-73.
  37. Browne JP, Cano SJ, Smith S. Using Patient-reported Outcome Measures to Improve Health Care: Time for a New Approach. Medical care. 2017;55(10):901-4.
  38. Rixon L, Baron J, McGale N, Lorencatto F, Francis J, Davies A. Methods used to address fidelity of receipt in health intervention research: a citation analysis and systematic review. BMC health services research. 2016;16(1):663.
  39. Cleanthous S, Marquis P, Strzok S, Pompilus F, Regnault A, Cano S. Why we should move mixed methods in psychometric research from a three-step to a" two-step''. ISOQOL; 2016; Copenhagen, Denmark.
  40. Cano SJ, Pendrill L. Why the quality of person-centred metrics counts in healthcare: past, principles and progress. University of Gothenburg Centre for Person-centred Care (GPCC) seminar; 2016; Göteborg, Sweden
  41. Cano SJ. PRO Measurement in 2016: Instrument Development and Modern Psychometrics. Patient Reported Outcomes in Surgery Conference, Plastic Surgery Education Foundation/Council of Medical Specialties; 2016; Washington DC, USA
  42. Cano S, Vosk T, Pendrill L, Stenner J. On trial: the compatibility of measurement in the physical and social sciences. IMEKO TC1-TC7-TC13 Joint Symposium; 2016; Berkeley, CA, USA
  43. Walton MK, Powers JH, 3rd, Hobart J, Patrick D, Marquis P, Vamvakas S, et al. Clinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task Force. Value Health. 2015;18(6):741-52.
  44. Symonds T, Wyrwich KW, Regnault A, Coons SJ. Moving the Science Forward: Tackling Key Psychometric and Methodological Issues Facing the Field of Clinical Outcome Assessment. ISPOR; 2015; Milan, Italy.
  45. Salzberger T, Cano S. Investigating a lack of discrimination between two adjacent response categories in the Rasch model for ordered categories in health measurement. International Outcome Measurement Conference; 2015; Chicago, IL, USA
  46. Regnault A, Herdman M. Using quantitative methods within the Universalist model framework to explore the cross-cultural equivalence of patient-reported outcome instruments. Qual Life Res. 2015;24(1):115-24.
  47. Regnault A, Hamel JF, Patrick DL. Pooling of cross-cultural PRO data in multinational clinical trials: how much can poor measurement affect statistical power? Qual Life Res. 2015;24(2):273-7.
  48. Petrillo J, Cano SJ, McLeod LD, Coon CD. Using classical test theory, item response theory, and Rasch measurement theory to evaluate patient-reported outcome measures: a comparison of worked examples. Value Health. 2015;18(1):25-34.
  49. Cano S, Hobart J. Individual vs group level measurement: Implications for health care outcome economics. International Outcome Measurement Conference; 2015; Chicago, IL, USA
  50. Cano S. Social Measurement: Three Problems, Five Challenges, One Solution. The Making of Measurement, CRASSH 2015; University of Cambridge, UK.
  51. Cano S. New Psychometric Methods - Implications for Surgery. Patient Reported Outcomes in Surgery Conference, American College of Surgeons; 2015; Washington, D.C., USA
  52. Moderator: Regnault A, Speakers: Symonds T, Houyez F, Arnould B. Can Mixed Methods Research be the Solution to the Challenges of Patient-Centered Outcome Research in the Context of Rare Diseases? . ISPOR; 2014; Amsterdam, The Netherlands.
  53. Fofana F, Bonnaud-Antignac A, Regnault A. A mixed method approach to help demonstrate saturation in qualitative research: applying Partial Least Square regression to qualitative data. 1st Mixed Methods International Research Association (MMIRA) Annual Conference; 2014; Boston, USA.
  54. Anthoine E, Moret L, Regnault A, Sebille V, Hardouin JB. Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures. Health Qual Life Outcomes. 2014;12:176.
  55. Acquadro C, Regnault A, Arnould B. Regulatory Issues in Pro Advertising: A Review of the Ddmac/Opdp Letters From 1998 To 2013 To Identify Pro Claims Violations and Examine Their Evolution Over Time. ISPOR; Amsterdam, The Netherlands, 2014.
  56. Petrillo J, Cano SJ, McLeod LD, Coon CD. Which paradigm for evaluating patient-reported outcome instruments? A comparison of classical test theory, item response theory, and rasch measurement theory. ISOQOL; 2013; Miami, FL, USA
  57. Moderator: Regnault A, Speakers: Patrick D, Carrita P, Pavlovic M. Demonstrating treatment benefit using clinical outcomes assessments in global clinical trials: how reliable are the assessments from cross-cultural settings? ISPOR; 2013; Dublin, Ireland.
  58. Fofana F, Bonnaud-Antignac A, Guillemin I, Marrel A, Beriot-Mathiot A, Regnault A. A mixed method approach to saturation: applying partial least square regression to qualitative data. ISOQOL 20th Annual Conference; Miami, FL, USA, 2013.
  59. Fofana F, Bonnaud-Antignac A, Guillemin I, Marrel A, Beriot-Mathiot A, Regnault A. Applying partial least square regression to further explore concept structure and interviewee profiles in qualitative research. ISOQOL 20th Annual Conference; Miami, FL, USA, 2013.
  60. Cleanthous S, Molin A, Senior V, Wearden A. The role of Health Psychologists in Applied Settings: An online survey and interviews with Health Psychology Practitioners. Health Psychology Update. 2013;22(1):30-7.
  61. Cano S. Developments in rating scale methods. Dementias & Neurodegenerative Diseases Research Network Annual Conference; 2013; London, UK
  62. Regnault A, Arnould B, Anfray C. Assessing Health Outcomes in a Global Clinical Research Setting: Challenges and Solutions to Manage Cultural Variability. ISOQOL; 2012; Budapest, Hungary.
  63. Regnault A, Hamel JF, Patrick DL. Pooling of cross-cultural PRO data in multinational clinical trials: How much can poor measurement affect statistical power? ISOQOL; Denver, CO, USA, 2011.
  64. Regnault A, Gilet H, Meunier J, Arnould B. Statistical approach to development and validation of patient-reported outcomes tools for individual decision-making. International symposium on Patient-Reported Outcome and Quality of Life; 2011; Paris, France.
  65. Regnault A, Arnould B, Anfray C. Managing Cultural Variability in PRO Measurement in a Global Clinical Research Setting. ISOQOL; 2011; Denver, USA.
  66. Marquis P, Caron M, Emery M-P, Scott J, Arnould B. The Role of Health-Related Quality of Life Data in the Drug Approval Processes in the US and Europe: A Review of Guidance Documents and Authorizations of Medicinal Products from 2006 to 2010. Pharm Med. 2011;25(3):147-60.
  67. Hobart JC, Cano SJ. Rasch analysis. In: Jenkinson, Peter, Bromberg, editors. Quality of Life Measurement in Neurodegenerative and Related Conditions. Cambridge: Cambridge University Press; 2011.
  68. Cano SJ, Hobart JC. The problem with health measurement. Patient Prefer Adherence. 2011;5:279-90.
  69. Cano SJ, Barrett LE, Zajieck JP, Hobart JC. Dimensionality is a relative concept. Multiple Sclerosis Journal. 2011;17(7):893-4.
  70. Viala-Danten M, Regnault A, Berdeaux G. The interpretation of patient-reported outcome data: a challenge for statisticians? International Society for Clinical Biostatistics; Montpellier, France, 2010.
  71. Lasch KE, Marquis P, Vigneux M, Abetz L, Arnould B, Bayliss M, et al. PRO development: rigorous qualitative research as the crucial foundation. Qual Life Res. 2010;19(8):1087-96.
  72. Hobart JC, Cano SJ, Thompson AJ. Effect sizes can be misleading: is it time to change the way we measure change? Journal of neurology, neurosurgery, and psychiatry. 2010;81(9):1044-8.
  73. Hobart JC, Cano SJ. Effect sizes can be misleading: Is it time to change the way we measure change? . ISOQOL; 2010; London, UK
  74. Gorecki C, Nixon J, Lamping DL, Brown JM, Cano S. The benefits of mixed methods in scale development II: Selecting optimal mode of administration ISOQOL; 2010; London, UK
  75. Gorecki C, Lamping DL, Nixon J, Brown JM, Cano S. The benefits of mixed methods in scale development I: The added value of Rasch analysis in pre-testing. ISOQOL; London, UK, 2010.
  76. Regnault A, Gilet H, Carita P, Arnould B. Exploring patients' satisfaction with anticoagulant treatmentby applying Structural Equation Models to the Perception of AntiCoagulant Treatment Questionnaire (PACT-Q). ISPOR; Paris, France, 2009.
  77. Regnault A, Carita P, Gilet H, Arnould B. Modélisation par équations structurelles de la satisfaction des patients vis-à-vis de leur traitement anticoagulant. Modèles et Apprentissage en Sciences Humaines et Sociales; 2009; Toulouse, France.
  78. Regnault A, Mear I, Marfatia S, Mollon P. Addressing cross-cultural issues with Patient-Reported Outcomes assessments to strengthen evidence obtained in an international context. ISPOR; 2008; Athens, Greece.
  79. Magnussen K, Quere S, Winkel P. Use of statistical process control in the production of blood components. Transfusion medicine (Oxford, England). 2008;18(3):190-6.
  80. Cano SJ, Hobart JC. Watch out, watch out, the FDA are about. Developmental medicine and child neurology. 2008;50(6):408-9.
  81. Cano SJ, Hobart JC. Item response (letter). The Psychologist. 2008;21(2):169.
  82. Regnault A, Arnould B. Partial least squares (PLS) discriminant analysis: a method of choice for developing clinical decision-support tools from patient reported outcomes (PRO) data. ISOQOL; Budapest, Hungary, 2007.
  83. Regnault A, de la Loge C, Bounekkar A, Lamure M. Le fonctionnement différentiel de l'item dans la démarche d'évaluation de la validité transculturelle des questionnaires patients. Sante et Systemique. 2006;9(1-2):175-203.
  84. Regnault A, de la Loge C, Bounekkar A, Lamure M. Detection of Differential Item Functioning with Ordinal Response Format: Application of Ordinal Log-Linear Models. 5th Conference of the International Test Commission; 2006; Brussels, Belgium.
  85. Regnault A, de la Loge C, Arnould B, Lamure M. Quantitative aspects of an Operational Procedure to Assess Cross-Cultural Equivalence: Description and Applications. ISOQOL; 2006; Lisboa, Portugal.
  86. Marquis P, Arnould B, Acquadro C, Roberts WM. Patient-Reported Outcomes and Health-Related Quality of Life in effectiveness studies: pros and cons. Drug Development Research. 2006;67(3):193-201.
  87. Cano SJ, O'Connor RJ, Thompson AJ, Hobart JC. Exploring disability rating scale responsiveness II: do more response options help? Neurology. 2006;67(11):2056-9.
  88. Smith SC, Cano SJ, Browne JP, Lamping DL, Black NA, van der Meulen J, et al. Patient-Reported Outcome Measures (PROMs) for Routine use in Treatment Centres: Recommendations Based on A Review of the Scientific Evidence. London: Health Services Research Unit, London School of Hygiene & Tropical Medicine, London, UK; 2005.
  89. Regnault A, de la Loge C, Conway K, Lamure M. How could quantitative methods contribute to the assessment of a PRO instrument's Cross-cultural Equivalence? ISOQOL; San Fransisco, USA, 2005.
  90. Marquis P, Keininger D, Acquadro C, De La Loge C. Translating and evaluating questionnaires: cultural issues for international research. In: Fayers P, Hays R, editors. Assessing Quality of Life in Clinical Trials. New York: Oxford University Press; 2005. p. 77-93.
  91. Hasle-Pham E, Arnould B, Spath HM, Follet A, Duru G, Marquis P. Role of clinical, patient-reported outcome and medico-economic studies in the public hospital drug formulary decision-making process: results of a European survey. Health Policy. 2005;71(2):205-12.
  92. Marquis P, Chassany O, Abetz L. A comprehensive strategy for the interpretation of quality-of-life data based on existing methods. Value Health. 2004;7(1):93-104.
  93. Barberger-Gateau P, Alioum A, Peres K, Regnault A, Fabrigoule C, Nikulin M, et al. The contribution of dementia to the disablement process and modifying factors. Dement Geriatr Cogn Disord. 2004;18(3-4):330-7.
  94. Arnould B, Regnault A, Girod I, Dubois D. Psychometric Tools designed for Medical Decision Making: Methodological and Analytical issues in item reduction, scoring, decision rule definition, and assessment of predictive validity. European Society for Medical Decision Making 9th Biennial Conference; 2004; Rotterdam, The Netherlands.
  95. Arnould B, de la Loge C, Abetz L, Regnault A, Duru G. Screeners, symptom and disability scales for use in clinical practice: their contribution to improve the use of drugs. ISPOR; 2004; Hamburg, Germany.
  96. Alioum A, Peres K, Verret C, Regnault A, Barberger-Gateau P. Determinants of progression and recovery through states of disability: use of a Markov model with piecewise constant intensities and covariates. Longevity, aging and degradation models; 2004; St Petersburg.
  97. Cano SJ, Warner TT, Hobart JC. What sample sizes for reliability and validity studies II: a prospective study. ISOQOL; 2003; Prague, Czech Republic
  98. Acquadro C, Berzon R, Dubois D, Leidy NK, Marquis P, Revicki D, et al. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health. 2003;6(5):522-31.
  99. Symonds T, Berzon R, Marquis P, Rummans TA. The clinical significance of quality-of-life results: practical considerations for specific audiences. Mayo Clin Proc. 2002;77(6):572-83.
  100. Chassany O, Sagnier PP, Marquis P, Fullerton S, Aaronson N, Group FtERIoQoLA. Patient-reported outcomes: the example of health-related quality of life – A European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Information Journal. 2002;36(1):209-38.
  101. Marquis P. Health-related quality of life (HRQL). Value Health. 2001;4(4):344-5.
  102. Jambon B, Marquis P, Burke LB, Kind P, Kline Leidy N, Barofsky I, et al. A decisive step towards the recognition of patient reported outcomes in clinical trials. Quality of Life Newsletter. 2001;26:24-5.
  103. Acquadro C, Jambon B, Ellis D, Marquis P. Language and Translation Issues. In: Spilker B, editor. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven Publishers; 1996. p. 575-85.